A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Phase: PHASE3
Conditions: Influenza, Human
Sponsor: Seqirus

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 1 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
CLINICAL STUDY PROTOCOL V118_20 Version 1.0
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to 
Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit 
Influenza Vaccine in Comparison with an MF59-Adjuvanted Trivalent Subunit 
Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine 
Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
Property of Seqirus Inc (hereafter referred to as Seqirus)
Confidential
May not be used, divulged, published or otherwise disclosed without written
consent of Seqirus.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 2 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
TABLE OF CONTENTS
TABLE OF CONTENTS ................................................................................................ 2
PROTOCOL SYNOPSIS V118_20 VERSION 1............................................................. 6
LIST OF ABBREVIATIONS........................................................................................ 27
1.
BACKGROUND AND RATIONALE ................................................................. 30
1.1
Background ..................................................................................................... 30
1.2
Rationale ......................................................................................................... 31
2.
OBJECTIVES...................................................................................................... 32
2.1
Primary Objectives .......................................................................................... 32
2.2
Secondary Immunogenicity Objectives ............................................................ 32
2.3 
Secondary Safety Objective: ............................................................................ 32
2.4
Exploratory Immunogenicity Objectives.......................................................... 32
3.
STUDY DESIGN................................................................................................. 33
3.1
Overview of Study Design............................................................................... 33
3.2
Study Period .................................................................................................... 34
3.3
Blinding Procedures......................................................................................... 35
3.4
Data Collection................................................................................................ 35
3.4.1
Data Collected from Subjects.................................................................... 35
3.4.2
Tools Used for Data Collection................................................................. 36
3.5
Collection of Clinical Specimens ..................................................................... 37
3.6
Stopping/Pausing Guidelines ........................................................................... 38
3.7
Data Monitoring Committee ............................................................................ 38
3.8
Premature Withdrawal from Study................................................................... 38
3.9
End of Study.................................................................................................... 40
4.
SELECTION OF STUDY POPULATION........................................................... 41
4.1
Inclusion Criteria ............................................................................................. 41
4.2
Exclusion Criteria ............................................................................................ 41
4.3
Criteria for Delay of Vaccination..................................................................... 42
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 3 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
5.
STUDY PROCEDURES...................................................................................... 43
5.1
Prevaccination Clinic Visit(s) .......................................................................... 43
5.1.1
Informed Consent ..................................................................................... 43
5.1.2
Screening.................................................................................................. 44
5.1.3
Enrollment................................................................................................ 47
5.1.4
Randomization.......................................................................................... 47
5.2
Vaccination Clinic Visit(s)............................................................................... 47
5.2.1
Postvaccination Procedures....................................................................... 48
5.2.2
Postvaccination Reminder Call ................................................................. 49
5.3
Postvaccination Clinic Visit and Safety Calls................................................... 49
5.3.1
Follow-up Clinic Visit .............................................................................. 50
5.3.2
Safety Follow-up Phone Calls................................................................... 51
5.4
Unscheduled Visits .......................................................................................... 52
5.4.1 Subjects Meeting Influenza-Like-Illness Criteria ......................................... 52
5.5
Study Termination Phone Call ......................................................................... 52
5.5.1
Early Termination Visit............................................................................. 53
6.
TREATMENT OF SUBJECTS ............................................................................ 54
6.1
Study Vaccines ................................................................................................ 54
6.2
Non-Study Vaccines ........................................................................................ 59
6.3
Vaccine Preparation and Administration.......................................................... 59
6.4
Vaccine Administration Error or Overdose of Vaccine..................................... 59
6.5
Prior and Concomitant Medications and Vaccines............................................ 60
6.6
Vaccine Supply, Labeling, Storage and Tracking ............................................. 62
7.
ASSESSMENTS.................................................................................................. 64
7.1
Safety Assessment ........................................................................................... 64
7.1.1
Solicited Adverse Events .......................................................................... 64
7.1.2
Unsolicited Adverse Events ...................................................................... 66
7.1.3
Evaluation of Adverse Events ................................................................... 66
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 4 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
7.1.4
Serious Adverse Events............................................................................. 68
7.1.5
Adverse Events of Special Interest ............................................................ 69
7.1.6
Methods for Recording and Reporting Adverse Events and Serious Adverse 
Events....................................................................................................... 69
7.1.7
Pregnancies............................................................................................... 70
7.1.8
Safety Laboratory Measurements.............................................................. 70
7.2
Efficacy Assessment........................................................................................ 71
7.3
Immunogenicity Assessment............................................................................ 71
8.
STATISTICAL CONSIDERATIONS.................................................................. 72
8.1
Endpoints......................................................................................................... 72
8.1.1     Primary Endpoints ................................................................................... 72
8.1.2
Secondary Immunogenicity Endpoints ..................................................... 73
8.1.3
Secondary Safety Endpoints..................................................................... 73
8.1.4
Exploratory Immunogenicity Endpoints.................................................... 74
8.2
Success Criteria ............................................................................................... 74
8.2.1
Success Criteria for Co-Primary Endpoints ............................................... 74
8.2.2
      Success Criteria for Secondary Objectives........................................... 75
8.3
Description of Analysis Sets ............................................................................ 75
8.3.1
All Enrolled Set ........................................................................................ 75
8.3.2 Full Analysis Set.......................................................................................... 76
8.3.3
Safety Set.................................................................................................. 76
8.3.4
Evaluable Set – Immunogenicity Analysis ................................................ 76
8.3.5
Per-Protocol Set........................................................................................ 76
8.3.6
Subgroups................................................................................................. 77
8.3.7
Protocol Deviations................................................................................... 77
8.4
Statistical Analysis Plan................................................................................... 78
8.4.1
Analysis of Demographic and Baseline Characteristics ............................. 78
8.4.2
Analysis of Primary Objective(s) .............................................................. 79
8.4.3
Analysis of Secondary Objective(s)........................................................... 83
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 5 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
8.4.4 Secondary Safety Objective ......................................................................... 85
8.4.5 Analysis of Exploratory Objectives.............................................................. 87
8.5
Sample Size and Power Considerations............................................................ 88
8.6
Interim Analysis .............................................................................................. 91
9.
SOURCE DOCUMENTATION, STUDY MONITORING AND AUDITING ..... 92
9.1
Source Documentation..................................................................................... 92
9.2
Study Monitoring, Auditing and Source Data Verification ............................... 93
10.
DATA MANAGEMENT ..................................................................................... 94
10.1 Data Entry and Management............................................................................ 94
10.2 Data Clarification ............................................................................................ 94
10.3 Data Protection ................................................................................................ 94
11.
RECORD RETENTION....................................................................................... 95
12.
USE OF INFORMATION AND PUBLICATION................................................ 96
13.
ETHICAL CONSIDERATIONS.......................................................................... 97
13.1 Regulatory and Ethical Compliance ................................................................. 97
13.2 Informed Consent Procedures .......................................................................... 97
13.3 Responsibilities of the Investigator and IRB/EC............................................... 97
13.4 Protocol Amendments...................................................................................... 99
14.
REFERENCE LIST............................................................................................ 100
APPENDIX 1: EXAMPLES OF PRE-EXISTING MEDICAL CONDITIONS FOR 
CALCULATION OF RISK SCORE .................................................................. 103
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 6 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
PROTOCOL SYNOPSIS V118_20 VERSION 1
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
Title of Study: A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, 
Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted 
Quadrivalent Subunit Influenza Vaccine in Comparison with an MF59-Adjuvanted 
Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit 
Influenza Vaccine Containing the Alternate B strain, in Adults Aged 65 Years and 
Above
Study Period: The total study period for a 
subject will be approximately 6 months 
following a single vaccination.
Clinical Phase: 3
Background and Rationale: Influenza is an infectious disease caused by the influenza 
virus, an orthomyxovirus with two clinically relevant types (types A and B). The disease 
is characterized by the abrupt onset of respiratory and systemic symptoms, such as 
fever, myalgia, headache, severe malaise, nonproductive cough, sore throat, and rhinitis, 
and occurs in epidemics throughout the northern and southern hemisphere winter 
months in temperate climates. During influenza epidemics, there is increased mortality 
among older adults (age > 65 years) and people with chronic diseases, as well as an 
increase in morbidity and hospitalization because of influenza-associated complications.
The ability of vaccination to prevent influenza in older adults appears to be lower 
compared with younger adults, possibly because of a less robust immune response after 
influenza vaccination. One way to increase immunogenicity of influenza vaccines is 
through the use of adjuvants, such as the squalene and water emulsion adjuvant, MF59.  
Fluad, Seqirus’ trivalent seasonal influenza vaccine adjuvanted with MF59, has been 
licensed for use in Europe since 1997 and in the US since 2015. It has been shown to 
generate significantly higher geometric mean hemagglutination inhibition (HI) titers and 
rates of seroconversion than a non-adjuvanted trivalent influenza vaccine comparator in 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 7 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
elderly subjects. Trivalent influenza vaccines contain just one B strain antigen. 
Influenza type B viruses, however, have separated into two distinct genetic lineages 
since 1985, Yamagata and Victoria. B strains from either lineage may circulate and 
cause infection, and mismatch may occur between circulating B strains and the strain 
contained in a trivalent vaccine. On average, influenza B strain accounts for 
approximately 25% of positive specimens in the US. Mismatches between the B strain 
in a trivalent vaccine and the circulating strain occur in approximately half of influenza 
seasons. To overcome this, several quadrivalent inactivated influenza vaccines are now 
licensed in the US, containing representative vaccine strains for both B-strain lineages, 
as well as the H1N1 and H3N2 A subtypes. 
The investigational product (aQIV) is an MF59-adjuvanted subunit inactivated 
quadrivalent influenza virus vaccine. A 0.5 mL dose is formulated to contain 15 mcg 
hemagglutinin (HA) of each included influenza virus strain, including representative 
strains of both B lineages. The aQIV formulation is consistent with the currently 
licensed Fluad trivalent influenza virus vaccine (aTIV), except that it contains an 
additional B influenza strain so that the total HA concentration is 60 mcg HA/0.5 mL 
dose, from four strains.
The aim of this study is to demonstrate that inclusion of an additional B vaccine strain 
elicits an immune response to the second B virus and does not adversely impact the 
patient’s immunogenicity response against strains previously included in trivalent 
formulations. Additionally, the aim is to demonstrate and confirm an acceptable safety 
and tolerability profile for the quadrivalent influenza vaccine formulation in the elderly 
population.
Data from this study will be used to support the licensure of aQIV for the prevention of 
seasonal influenza in adults ≥ 65 years of age.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 8 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
Study Objectives:
Co-Primary Immunogenicity Objectives:
1. To demonstrate that vaccination with aQIV elicits an immune response that is 
not inferior to that of an aTIV containing the same virus strains as the US 
licensed adjuvanted influenza vaccine (Fluad, aTIV-1), and an aTIV 
containing the alternate B strain (aTIV-2) among adults ≥65 years of age.
2. To assess the immunogenicity of aQIV in adults ≥65 years of age, based on 
the CBER (Center for Biologics Evaluation and Research) recommendations.
Secondary Immunogenicity Objectives:
The secondary objectives of the study are to assess the following, among adults aged ≥ 
65 years: 
1. To characterize the immunogenicity of aQIV, the aTIV-1 containing the same 
virus strains as the US licensed adjuvanted trivalent influenza vaccine, and the 
aTIV-2 containing the alternate B strain, by hemagglutination inhibition (HI). 
2. To demonstrate the immunological superiority of aQIV compared to aTIV-1 and 
aTIV-2 for the B strain that is not included in each TIV vaccine separately;
Secondary Safety Objective:
1. To assess safety and tolerability of aQIV, aTIV-1, and aTIV-2 among adults >
65 years of age.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 9 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
Exploratory Immunogenicity Objectives:
1. To explore the association between HI immune response after administration 
of aQIV or the aTIV-1, containing the same virus strains as the US-licensed 
adjuvanted trivalent influenza vaccine, and the aTIV-2 containing the 
alternate B strain by baseline characteristics.
2. Characterization of the immunogenicity of aQIV using other immunological 
assays (e.g., virus neutralization [MN] or anti-neuraminidase antibody assays 
may be performed).
Both exploratory objectives may be performed using either homologous or heterologous 
strains, or both.
Study Design: This phase 3 study is a randomized, double-blinded, comparator 
controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 
adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an adjuvanted 
trivalent influenza vaccine (aTIV-2), containing the alternate B strain. All study vaccine 
administration will be a single dose, and consistent with the current license for aTIV-1.
The study will be conducted in approximately 1778 male and female adults aged 65 
years and older who are healthy or have co-morbidities which increase their risk of 
complications from influenza infection. Subjects will be randomized to one of the three 
treatment groups in a 2:1:1 ratio. An Interactive Response Technology (IRT) system 
will be used for subject randomization.
Subjects will provide serological specimens during the two mandatory clinic visits 
before and after vaccination on Day 1 and Day 22 for measurement of immune 
responses in routine influenza assays. Each subject will complete a Diary Card for 
solicited local and systemic adverse events for 7 days after vaccination. Safety 
information will also be collected for all unsolicited AEs for 21 days following 
vaccination; and for the full duration of study participation for serious AEs (SAEs), AEs 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 10 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
leading to withdrawal from the study, new onset of chronic diseases (NOCDs), AEs of 
special interest (AESIs), and concomitant medications associated with these events. 
Three scripted safety telephone calls will facilitate the collection of these safety data 
during the study period, and one reminder phone call will occur during the first few 
days after vaccination to remind the subject on the completion of the Diary Card.
An unscheduled study visit may be performed at any time during the study to further 
evaluate safety information described on the telephone.
Any subject who manifests signs of an influenza-like illness during the Treatment
Period (Days 1-22) will be evaluated by real time reverse transcription polymerase 
chain reaction (RT-PCR) testing of a nasopharyngeal (NP) specimen for influenza. 
Subjects with onset of ILI and RT-PCR-confirmed influenza during the Treatment
Period (Days 1-22) will be removed from the Per Protocol Set (PPS) in the 
immunogenicity analyses. ILI will also be recorded as an adverse event.
Number of Subjects planned: Approximately 1778 subjects will be enrolled into this 
study. In order to have 800 evaluable subjects in the aQIV group and 400 evaluable 
subjects in each aTIV group, and considering 10% for drop-outs, approximately 1778 
are needed to be enrolled into this study. The subjects will be distributed among the 
vaccine groups in a ratio of 2:1:1 (aQIV:aTIV-1:aTIV-2).
Study Population and Subject Characteristics: This study will enroll males and 
females ≥65 years old who are healthy or have co-morbidities. The list of inclusion and 
exclusion criteria is included in protocol Section 4, Selection of Study Population.
Study Procedures: 
Written informed consent must be obtained prior to any study-related procedures. The 
informed consent process may be conducted up to 10 days before day of vaccination 
(Day 1). 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 11 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
Treatment Period: Day 1 through Day 22
After informed consent is signed by the subject or legal representative, on and prior to 
vaccination on Day 1, evaluations will be performed and will include relevant medical 
history, physical examination, and vital signs. A blood sample will be collected from all 
eligible subjects for influenza-specific serology testing. All eligibility assessments need 
to be completed prior to blood sample collection. Subjects will be assessed for risk of 
complications from influenza using the standardized scoring system described by Hak 
(2004).
All eligible subjects will then receive a single dose of 0.5 mL of study vaccine to which 
they were assigned, administered intramuscularly in the deltoid muscle, preferably of 
the non-dominant arm.
After vaccination, all subjects will remain under medical supervision at the study site 
for at least 30 minutes to be monitored and evaluated for local and systemic adverse 
events (AEs).
Subjects will receive a thermometer, a ruler, and a Diary Card, along with instructions 
to ensure proper completion; they will note any occurrence of solicited local and
systemic AEs, and record their oral temperatures, preferably in the evening, for events 
occurring on Day 1 through Day 7. The Diary Card will only be used to collect solicited 
adverse events and temperature measurements.
A reminder telephone call will be made on Day 3 (window, Day 2 to Day 4) to remind 
the subject to complete the Diary Card and to return the Diary Card at the Day 22 clinic 
visit, when the Diary Card data and information on unsolicited AEs will be verbally 
collected and reviewed.
A scripted safety telephone call will be made by site staff to subjects on Day 15 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 12 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
(window: Day 12 to day 18) to collect any unsolicited AEs and any use of concomitant 
medications: these will be captured in source documents and the electronic Case Report 
Form (CRF). Subjects with symptoms of ILI will be reminded to return to the study site 
for nasopharyngeal swab testing. 
Subjects will return to the clinic on Day 22 (window, Day 19 to Day 25) for a medical 
examination, and to provide a serum sample for serologic testing. During this visit the
Diary Card will be collected and all unsolicited AEs and concomitant medication use 
(occurring after vaccination between Day 1 and Day 22) will be documented in the 
subject’s source records and captured in the CRF.
Any subject who manifests signs of an influenza-like illness (ILI, defined as at least one 
of the following respiratory symptoms [new onset or exacerbation of pre-existing 
condition]: sore throat, cough, sputum production, wheezing, or difficulty breathing; 
concurrently with at least one of the following systemic symptoms: temperature of 
>37.2°C/ 99°F, chills, tiredness, headache, or myalgia) during the Treatment Period 
(Days 1-22) will be asked to come in to the site within 3 days of the onset of the ILI in 
order to have a nasopharyngeal (NP) swab collected for evaluation of the presence of 
influenza virus using RT-PCR. However, samples will be accepted if collected up to 6 
days following the day of ILI onset. Swabs will be sent to a qualified central laboratory
as specified in the Clinical Investigator Laboratory Manual.
Follow-up Period: Day 23 through Day 181
A scripted safety telephone call will be made on Day 91 (window: Day 84 to Day 98) to 
collect only those unsolicited AEs that are: serious AEs (SAEs), AEs leading to study 
withdrawal, new onset of chronic diseases (NOCDs), adverse events of special interest 
(AESIs); and concomitant medications associated with these events. 
A scripted safety telephone call will be made on Day 181 (window: Day 167 to Day 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 13 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
195) for assessment of SAEs, AEs leading to study withdrawal, NOCDs, and AESIs; 
and concomitant medications associated with these events.
An unscheduled study visit may be performed as necessary for further evaluation of 
safety information that is described on the telephone that is to be investigated further at 
any time during the study.
If a subject withdraws from the study, they will be asked to undergo a final assessment 
for safety.
Study Vaccines: Regardless of the type of a vaccine assigned in the trial, subjects will 
receive a 0.5 mL dose. All three influenza vaccines are made similarly, with the 
exception of the influenza strains included.
Quadrivalent Influenza Test Vaccine (aQIV, investigational vaccine)
An adjuvanted inactivated subunit quadrivalent influenza vaccine, administered as one 
0.5 mL intramuscular dose into the deltoid muscle. The vaccine is presented in a 
prefilled needleless syringe. Each 0.5 mL dose contains 15 mcg hemagglutinin (HA) 
from each of the following four influenza strains (recommended by the World Health 
Organization for the 2017-2018 Northern Hemisphere influenza season for quadrivalent 
vaccines:

15 mcg per 0.5 mL dose A/Michigan/45/2015 (H1N1)pdm09-like virus; 

15 mcg per 0.5 mL dose A/Hong Kong/4801/2014 (H3N2)-like virus; 

15 mcg per 0.5 mL dose B/Brisbane/60/2008-like virus (B/Victoria lineage):

15 mcg per 0.5 mL dose B/Phuket/3073/2013-like virus (B/Yamagata lineage).
Licensed Trivalent Influenza Comparator Vaccine 1 (aTIV-1, Trade name: Fluad)
An adjuvanted inactivated subunit trivalent influenza vaccine, administered as one 0.5 
mL intramuscular dose into the deltoid muscle. The vaccine is presented in a prefilled 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 14 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
needleless syringe.
Each 0.5 mL dose contains 15 mcg HA from each of the following three influenza 
strains (two influenza A strains and one B strain recommended for a trivalent influenza 
vaccine by the World Health Organization for the 2017-2018 Northern Hemisphere 
influenza season:

15 mcg per 0.5 mL dose A/Michigan/45/2015 (H1N1)pdm09-like virus; 

15 mcg per 0.5 mL dose A/Hong Kong/4801/2014 (H3N2)-like virus; 

15 mcg per 0.5 mL dose B/Brisbane/60/2008-like virus (B/Victoria lineage).
Trivalent Influenza Comparator Vaccine 2, with alternate B strain (aTIV-2, 
investigational vaccine)
An adjuvanted inactivated subunit trivalent influenza vaccine, administered as one 0.5 
mL intramuscular dose into the deltoid muscle. The vaccine is presented in a prefilled 
needleless syringe. Each 0.5 mL dose contains 15 mcg HA from each of the following 
three influenza strains (two influenza A strains recommended for a trivalent influenza 
vaccine by the World Health Organization for the 2017-2018 Northern Hemisphere 
influenza season.and the alternate B strain to that recommended for TIV:

15 mcg per 0.5 mL dose A/Michigan/45/2015 (H1N1)pdm09-like virus; 

15 mcg per 0.5 mL dose A/Hong Kong/4801/2014 (H3N2)-like virus; 

15 mcg per 0.5 mL dose B/Phuket/3073/2013-like virus (B/Yamagata lineage).
Co-Primary Immunogenicity Endpoint(s): 
The immunogenicity of study vaccines will be assessed 21 days (ie, on Day 22) after 
vaccine administration by measuring the hemagglutination inhibition (HI) antibody 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 15 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
titers to the four virus strains included in the vaccines.
The noninferiority of aQIV compared to aTIV-1, and to aTIV-2 will be assessed for the 
eight co-primary endpoints of HI geometric mean titer (GMT) and seroconversion rate 
(SCR) for each virus strain included in the vaccines as follows:
The GMT ratio* for the A/H1N1 strain;
The GMT ratio for the A/H3N2 strain;
The GMT ratio for the B strain (Yamagata lineage);
The GMT ratio for the B strain (Victoria lineage);
The difference between the SCR**for the A/H1N1 strain;
The difference between the SCR for the A/H3N2 strain;
The difference between the SCR for the B strain (Yamagata lineage);
The difference between the SCR for the B strain (Victoria lineage).
Immunogenicity results obtained from aTIV-1 and aTIV-2 for both A/H1N1 and 
A/H3N2 strains will be pooled for comparison with aQIV.
*The GMT ratio is defined as the geometric mean of the post-vaccination (Day 22) HI titer for aTIV-1 (or 
aTIV-2) over the geometric mean of postvaccination (Day 22) HI titer for aQIV.
**The SCR is defined as the percentage of subjects with either a prevaccination HI titer < 1:10 and a 
post-vaccination HI titer ≥ 1: 40 or a prevaccination HI titer ≥ 1:10 and a ≥ 4-fold increase in 
postvaccination HI titer.
The second co-primary immunogenicity objective for aQIV will be assessed 21 days 
after vaccine administration by applying CBER criteria for the elderly population for 
each of the 4 strains included in aQIV:
The percent of subjects achieving seroconversion for HI antibody
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 16 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
The percent of subjects achieving an HI antibody titer ≥ 1:40
The study is considered successful if the all co-primary endpoints are achieved.
Co-primary Immunogenicity Objective 1 - Criteria to demonstrate noninferiority:
In line with the FDA Guidance on seasonal inactivated influenza vaccines (Guidance for 
Industry Clinical Data Needed to Support Licensure of Seasonal Inactivated Influenza 
Vaccines 2007), aQIV will be considered to be noninferior to aTIV-1, containing the 
same virus strains as the US licensed adjuvanted trivalent influenza vaccine, and aTIV-
2, containing the alternate B strain if, for each of the four strains, the following 
statistical criteria are met:
The upper bound of the two-sided 95% confidence interval (CI) for the ratio of 
the GMTs (GMTr) does not exceed 1.5. The GMTr will be calculated as GMT 
aTIV/GMT aQIV; and
The upper bound of the two-sided 95% CI for the difference between the SCRs 
does not exceed 10%. The difference in SCRs will be calculated as SCR aTIV–
SCR aQIV
Co-primary Immunogenicity Objective 2 – CBER Criteria:
The endpoints for percent of subjects vaccinated with aQIV achieving seroconversion 
and HI titer ≥ 1:40 at Day 22 will be assessed against the criteria described in CBER 
Guidance Clinical Data Needed to Support the Licensure of Seasonal Inactivated 
Influenza Vaccines (FDA, 2007):
The lower bound of the two-sided 95% confidence interval for the percentage of 
subjects achieving seroconversion for HI antibody should meet or exceed 30%.

The lower bound of the two-sided 95% confidence interval for the 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 17 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
percentage of subjects achieving an HI antibody titer ≥ 1:40 should meet or 
exceed 60%.
The statistical evaluation consists of the observed proportion together with the 
corresponding two-sided 95% CI interval per strain. 
No adjustment for type I error for multiplicity will be made. The study is successful if 
the co-primary immunogenicity objectives are achieved.
Secondary Immunogenicity Endpoint(s): 
The measures of immunogenicity of aQIV, aTIV-1 and aTIV-2 used for 
Secondary objective 1 as determined by the HI assay against homologous 
strains at Day 1 and 22 (unless indicated otherwise), include the following:
o
GMT: Geometric mean of HI titers on Day 1 and Day 22; 
o
Geometric mean ratio (GMR)*: The geometric mean of the fold increase of 
postvaccination HI titer over the prevaccination HI titer (Day 22/Day 1);
o
The percentage of subjects with a titer ≥1:40 at Day 1 and Day 22;
o
SCR: the percentage of subjects with either a prevaccination HI titer < 1:10 
and a postvaccination HI titer ≥ 1:40 or a prevaccination titer ≥ 1:10 and a 
≥ 4-fold increase in postvaccination titer on Day 22.
For secondary objective 2 the immunologic superiority HI antibody responses of 
the alternate B strain (the influenza B strain included in the aQIV but not in the 
aTIV formulation) in aQIV will be assessed separately, by the endpoints of the 
ratio of HI GMT and the difference of SCR for each B virus strain 21 days after 
the last vaccination in subjects. Superiority of aQIV over aTIV-1 and aTIV-2 
for antibody response to the alternate B strain will be assessed using the GMT 
ratio (aTIV/aQIV) and difference in SCR (aTIV – aQIV) at Day 22. Point 
estimates and 95% confidence limits will be obtained as described for the 
primary endpoint. Superiority will be declared if the upper limit of the two-
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 18 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
sided 95% CI for the difference in SCR (aTIV – aQIV) is < 0 and the upper 
limit of the two sided 95% CI for the GMT ratio (aTIV/aQIV) is < 1 for both B 
strains
Secondary Safety Endpoints:
Safety and tolerability will be assessed by the frequency and severity of:

Solicited local and systemic adverse events (AEs) for 7 days following 
vaccination (Day 1 through Day 7)

All unsolicited AEs for 21 days following vaccination (Day 1 through Day 
22)

Serious AEs (SAEs), AEs leading to withdrawal from the study, new onset of 
chronic diseases (NOCDs), AEs of special interest (AESIs), and concomitant 
medications associated with these events as collected from Day 1 through 
Day 181.
Exploratory Endpoint(s): 

Exploratory immunogenicity endpoints include:
o
GMTs: Geometric mean HI titers (GMTs) at Day 1 and Day 22
o
SCRs: Percentage of subjects with either a prevaccination HI titer < 1:10 
and a postvaccination HI titer ≥ 1:40, or a prevaccination titer ≥ 1:10 and a 
≥ 4-fold increase in postvaccination titer at Day 22

In case of any additional optional immunogenicity analyses, such as MN, or 
assessments using heterologous influenza strains, the immune response will 
be characterized in a similar manner as described in the secondary 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 19 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
immunogenicity endpoints section above.
Further details regarding the endpoints and analyses of these assays will be described in 
the Statistical Analysis Plan (SAP) prior to unblinding.
Statistical Analyses:
Sample Size Estimation:
aQIV will be tested against aTIV comparators. The treatment randomization ratio is 
2:1:1 (aQIV: aTIV-1: aTIV-2). This study is powered to achieve 80% power to 
demonstrate noninferiority over 8 co-primary endpoints, seroconversion rates for 4 
strains, GMT for 4 strains using a one-sided alpha of 0.025 for each comparison. No 
adjustment for multiple endpoints will be made.
For comparisons of SCR a noninferiority margin of 10% (aTIV – aQIV) will be 
employed. It is assumed that the SCRs for A/ H1N1, A/ H3N2 and B strains for TIV are 
73%, 73% and 40% respectively. These estimates are based on the estimated SCR rates 
of historical data, namely study protocol V70_27. It has been assumed that there is no 
difference in terms of SCR between aQIV and aTIV for all strains. For comparison of 
GMT ratio a noninferiority margin of 1.5 (aTIV/aQIV) will be employed. It is assumed 
that there is no difference between aQIV and aTIV (i.e. a ratio of 1) and that the 
standard deviation of log (titer) is 1.2.
Under these assumptions, N evaluable = 800 in the aQIV group and 400 in each aTIV 
group providing 800 and 800 subjects receiving aQIV and aTIV respectively for 
comparisons of A strains, and 800 and 400 subjects receiving aQIV and aTIV 
respectively for comparisons of B strains. This provides a total N evaluable = 1600. 
These numbers provide 99.45% power to detect differences in SCR for each A strain 
and 91.29 % power for each B strain, providing overall 82.42% power for the 4 SCR 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 20 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
tests.
For GMT ratio tests each A strain test will have 100% power and each B strain test will 
have 99.98% power, providing 99.96% power for the 4 GMT ratio tests and 
consequently 82.39% power for the 8 co-primary endpoints.  Overall 1600 evaluable 
subjects will be required. Allowing for a 10% drop-out N=1778 subjects will be 
recruited (Sample size calculations were performed using PASS v12).
The immunogenicity was powered to meet the criteria prespecified in the CBER 
guidance for acceptable immunogenicity: namely, 

the lower bound of the two-sided 95% confidence interval for the percent of 
subjects achieving seroconversion should exceed 30%, and 

the lower bound of the two-sided 95% confidence interval for the percent of 
subject achieving HI antibody titer ≥ 40 should exceed 60%
With a sample size of N=800 (evaluable) subjects for the aQIV group if the population 
SCR for A/ H1N1, A/ H3N2 and B strains for TIV is 73%, 73% and 40% respectively 
then the probability of observing a seroconversion rate that is significantly greater than 
30% is approximately 100% (for the A/H1N1), 100% for A/H3N2 and 100% (for the B-
strains).
With a sample size of N=800 (evaluable) subjects for the aQIV group, if the population
titer > 1:40 rates for A/ H1N1, A/ H3N2 and B strains for TIV are 91%, 99% and 64.6% 
respectively (as observed in V70_27) then the probability of observing a SP rate that is 
significantly greater than 60% is approximately 100% (for the A/H1N1), 100% for 
A/H3N2 and 76.47% (for the B-strains).
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 21 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
Analysis Populations:
The All Enrolled Set will comprise all subjects providing informed consent who are 
assigned a subject ID, and provide demographic and/or screening information.
The Full Analysis Set (FAS) will comprise all subjects randomized and receive a study 
vaccine. 
The Safety Set will comprise all subjects in the FAS who received at least one dose of 
study vaccine and have provided follow-up safety data. This population will be used to 
summarize and list all safety information.
The Evaluable Population will comprise all subjects in the FAS who:

receive vaccine on Day 1;

provided pre- and postvaccination blood samples;

did not experience laboratory-confirmed influenza illness; between Day 1 and 
Day 22; and

did not receive any contraindicated medication during the study that is medically 
assessed to potentially impact immunogenicity results.
The Per Protocol Set will comprise all subjects in the evaluable population who do not 
have any protocol deviations felt to potentially impact immunogenicity results.
The Per Protocol Set will be the primary population of interest for the 
primary/secondary immunogenicity analysis and a supporting analysis will be 
performed using the Evaluable Population. Duplicate tables of primary and secondary 
immunogenicity analyses may also be produced based on the Evaluable population if 
there is >1% difference in the total number of subjects between the Per-Protocol 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 22 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
Population and the Evaluable Population.
Evaluation of Co-Primary Immunogenicity Endpoints:
Noninferiority
To determine the GMT ratio (adjusted analysis) a general linear model (GLM) will be 
fitted on log transformed (base 10) post-vaccination HI titer as the outcome variable and 
terms for covariates: vaccine treatment, pre-vaccination HI titer, age stratum (≥65-74, 
≥75-84, and ≥85years), gender, vaccination history, age-by-vaccine interaction and 
study site. Potential covariate interaction effects will also be examined in the fit of the 
GLM. From the model, an adjusted difference in least square means (on the log scale) will 
be produced with 95% confidence limits. The estimated difference and the confidence limits 
will be back transformed to obtain an adjusted GMT ratio with 95% confidence limits. Each 
of the four strains will be analyzed separately. The adjusted GMT ratio will be the result for 
which the non-inferiority assessment of the HI GMT co-primary endpoint will be based on. 
The statistical models might be reduced in case they fail to converge. Further details 
will be provided in the Statistical Analysis Plan
The complete set of covariates that will be used in the model to calculate the adjusted 
GMT ratio will include treatment group (3 treatments), age sub-group, sex (male or 
female), influenza vaccination received prior year (Y or N), prevaccination mean GMT 
titer (value) and investigator site (site identifier)
The GLM specification is: Adjusted Analysis GMT Model: Log-transformed Post-
vaccination HI Titer = Vaccine + Age Strata + Gender + Vaccination History [y/n] + 
Log-transformed Prevaccination HI Titer + Site + Age Strata*Vaccine.
The measure of the unadjusted GMT ratio based on postvaccination GMTs only will 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 23 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
also be presented.
In line with the FDA Guidance on seasonal inactivated influenza vaccines (Guidance 
for Industry Clinical Data Needed to Support Licensure of Seasonal Inactivated 
Influenza Vaccines 2007).  aQIV will be considered to be non-inferior to aTIV if, for 
each of the four strains, the following statistical criteria are met: 

The upper bound of the two-sided 95% Confidence Interval (CI) for the ratio of the 
GMTs does not exceed 1.5. The GMT ratio will be calculated by 
GMTaTIV/GMTaQIV. 

The upper bound of the two-sided 95% CI for the difference between the SCRs does 
not exceed 10%. The difference in SCR will be calculated by SCRaTIV – SCRaQIV.
CBER Criteria:
To achieve the co-primary CBER criteria: 

The lower bound of the two-sided 95% confidence interval for the percentage of 
subjects achieving seroconversion for HI antibody should meet or exceed 30%.

The lower bound of the two-sided 95% confidence interval for the percentage of 
subjects achieving an HI antibody titer ≥ 40 should meet or exceed 60%.
To meet the CBER criteria, both endpoints should be met for each strain included in 
aQIV arm.
The statistical evaluation consists of the observed proportion together with the 
corresponding two-sided exact 95% confidence interval per strain. No adjustment for 
type I error for multiplicity is made.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 24 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Name of Sponsor:
Seqirus Inc.
Protocol 
number:
V118_20
Generic name of study vaccine(s):
MF59-adjuvanted Quadrivalent Subunit Inactivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59-adjuvanted Trivalent Subunit 
Inactivated Egg-derived Influenza Vaccine (aTIV-1);
MF59-adjuvanted Trivalent Subunit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV-2).
Secondary Immunogenicity Endpoints:
Characterization of immunogenicity of aQIV, aTIV-1 and aTIV-2:
The measures of immunogenicity of aQIV, aTIV-1 and aTIV-2 will be assessed in terms 
of HI antibodies. Serum HI antibody titers against the 4 influenza vaccine strains will be 
used to calculate: 

GMT: Geometric mean of HI titers on Day 1 and Day 22; 

GMR: The geometric mean of the fold increase of post- vaccination HI titer over 
the pre-vaccination HI titer (Day 22/Day 1;

The percentage of subjects with a titer ≥ 1:40 at Day 1 and Day 22;

SCR:  the percentage of subjects with either a prevaccination HI titer < 1:10 and 
a postvaccination HI titer ≥ 1:40 or a prevaccination titer ≥ 1:10 and a ≥ 4-fold 
increase in postvaccination titer on Day 22.
Superiority of immunologic response for aQIV vs aTIV:
Superiority of aQIV over aTIV-1 and aTIV-2 for antibody response to the alternate B 
strain will be assessed using the GMT ratio (aTIV/aQIV) and difference in SCR (aTIV –
aQIV) at Day 22. Point estimates and 95% confidence limits will be obtained as 
described for the primary endpoint. Superiority will be declared if the upper limit of the 
two-sided 95% CI for the difference in SCR (aTIV – aQIV) is < 0 and the upper limit of 
the two sided 95% CI for the GMT ratio (aTIV/aQIV) is < 1 for both B strains.
Interim Analysis: An interim analysis is not planned for this study.
Data Monitoring Committee: An independent Data Monitoring Committee will not be 
utilized for the study.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 26 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
1. The invitation to participate and the informed consent process must be conducted within 10 days before the day of vaccination (Day 1) 
2. Confirm that patient has had the opportunity to ask questions and consent form(s) are signed prior to any V118_20 procedures being performed.
3. Procedure to be performed prior to vaccination. All eligibility criteria must be met before any study procedures (eg., blood sampling) can be performed. 
4. Physical examination must be performed by a qualified health care practitioner in accordance with local regulations and licensing requirements designated 
within the Site Responsibility Delegation Log.
5. Vaccination should occur only after the pre-dose blood sample collected.
6. After vaccination, the subject will remain under medical supervision for at least 30 minutes and observed for local and systemic AE and unsolicited AEs. A
body temperature measurement (preferably oral) will be taken.
7. A Diary Card, thermometer and ruler will be dispensed at Day 1.  Subject will receive instruction on diary completion and thermometer and ruler use. 
8. On Day 1 approximately 6 hours after the vaccination or prior to going to bed at the latest, and daily thereafter through Day 7, solicited local and systemic 
adverse events including other adverse events (i.e., body temperature measurements and use of analgesics/antipyretics) will be reported daily by the subject in the 
Diary Card.
9. The reminder call at Day 3 will be made by site staff to remind the subject to complete the Diary Card. In the safety calls at Day 15, Day 91 and day 181, 
subjects will be interviewed by site staff using a scripted interview for collection of safety data. These safety data will be collected in source documents by the 
individuals performing the interviews.
10. The subject will be asked to contact the site staff if the subject experiences ILI symptomsa during the interval between Day 1 and Day 22 (i.e., up to and 
including the day of the Day 22 blood sample). The subject should visit the site within 3 days of the onset of the ILI in order for a nasopharyngeal swab sample 
to be taken, however samples will be accepted if collected up to 6 days following the day of ILI onset. The sample will be sent to the central laboratory for RT-
PCR analysis.
a defined as at least one of the following respiratory symptoms: sore throat, cough, sputum production, wheezing, or difficulty breathing; concurrently with at 
least one of the following systemic symptoms: oral temperature of >37.2°C/ 99°F, chills, tiredness, headache, or myalgia.
11. All adverse events through the day 22 visit, and medications used to treat them.
12. Any subject who terminates the study prematurely after receiving a vaccination should have a termination visit/call (Section 5.5.1).
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 27 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
LIST OF ABBREVIATIONS
AE 
Adverse Event
AESI 
Adverse Event of Special Interest
CBER 
Center for Biologics Evaluation and Research
CDC 
Centers for Disease Control and Prevention
CI 
Confidence Interval
CRF 
Case Report Form
CRO 
Contract Research Organization
CSR 
Clinical Study Report
DCF 
Data Clarification Form
DMC 
Data Monitoring Committee
EC 
Ethics Committee
EDC 
Electronic Data Capture
EMA 
European Medicines Agency
FAS 
Full Analysis Set
FDA 
United States Food and Drug Administration
GCP 
Good Clinical Practices
GMR 
Geometric Mean Ratio
GMT 
Geometric Mean Titer
GMTr
Geometric Mean Titer Ratio
HA 
Hemagglutinin
HI 
Hemagglutination Inhibition
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 28 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
HIPAA 
Health Insurance Portability and Accountability Act
IB 
Investigator’s Brochure
ICF 
Informed Consent Form
ICH 
International Council (previously Conference) on Harmonisation of 
Technical Requirements for Pharmaceuticals for Human Use
ILI 
Influenza-Like Illness
IM
Intramuscular
IRB 
Institutional Review Board
IRT 
Interactive Response Technology
MedDRA 
Medical Dictionary for Regulatory Activities
MN 
Microneutralization
NA
Neuraminidase
NOCD 
New Onset of Chronic Disease
NP 
Nasopharyngeal
PCR 
Polymerase Chain Reaction
PP 
Per Protocol
PPS 
Per Protocol Set
PV 
Pharmacovigilance
aQIV 
Adjuvanted Quadrivalent Influenza Vaccine
QIV 
Quadrivalent Influenza Vaccine
RT-PCR 
Reverse Transcriptase Polymerase Chain Reaction
SAE 
Serious Adverse Event
SAP 
Statistical Analysis Plan
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 29 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
SC 
Seroconversion
SCR
Seroconversion Rate
SDA 
Source Data Agreement
SOC 
System Organ Class
SOP 
Standard Operating Procedure
aTIV
Adjuvanted Trivalent Influenza Vaccine
TIV 
Trivalent Influenza Vaccine
WHO 
World Health Organization
VSAE
Vaccine Serious Adverse Event
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 30 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
1.
BACKGROUND AND RATIONALE
1.1
Background
Influenza is an infectious disease caused by the influenza virus, an orthomyxovirus with 
two clinically relevant types (types A and B). The disease is characterized by the abrupt 
onset of respiratory and systemic symptoms, such as fever, myalgia, headache, severe 
malaise, nonproductive cough, sore throat, and rhinitis (Temte and Prunuske, 2010), and 
occurs in epidemics throughout the northern and southern hemisphere winter months in 
temperate climates. In general, influenza is resolved within two to seven days, although 
symptoms of cough and malaise may be prolonged. However, for some people, notably 
older adults and those with chronic diseases (such as pulmonary or circulatory disorders, 
metabolic disorders such as diabetes mellitus, renal dysfunction, or immunosuppression), 
influenza can exacerbate underlying medical conditions and/or lead to secondary viral or 
bacterial pneumonia (Rothberg et al., 2008; Fiore et al., 2009). During influenza 
epidemics, there is increased mortality among older adults (age > 65 years) and people 
with chronic diseases, as well as an increase in morbidity and hospitalization because of 
influenza-associated complications (Fiore et al. 2009; Monto 2008).
The ability of vaccination to prevent influenza in older adults appears to be lower 
compared with younger adults (Osterholm, Kelley et al., 2012; Beyer, McElhaney et al.,
2013), possibly because of a less robust immune response after influenza vaccination
(Goodwin, Viboud et al., 2006; Sasaki, Sullivan et al., 2011). One way to increase 
immunogenicity of influenza vaccines is through the use of adjuvants, such as the 
squalene and water emulsion adjuvant, MF59.  Fluad, Seqirus’ trivalent seasonal 
influenza vaccine adjuvanted with MF59, has been licensed for use in Europe since 1997 
and in the US since 2015. It has been shown to generate significantly higher geometric 
mean hemagglutination inhibition (HI) titers and rates of seroconversion than a non-
adjuvanted trivalent influenza vaccine comparator in elderly subjects (Frey et al., 2014).  
Trivalent influenza vaccines contain just one B strain antigen. Influenza type B viruses, 
however, have separated into two distinct genetic lineages since 1985, Yamagata and 
Victoria (Rota et al., 1990). B strains from either lineage may circulate simultaneously 
(Ambrose and Levin, 2012) and cause infection, and mismatch may occur between 
circulating B strains and the strain contained in a trivalent vaccine (Lo, Chuang et al.,
2013). On average, influenza B strain accounts for approximately 25% of positive 
specimens in the US. Mismatches between the B strain in a trivalent vaccine and the 
circulating strain occur in approximately 5 out of every 10 influenza seasons
(Belshe, 2010). To overcome this, several quadrivalent inactivated influenza vaccines are 
now licensed in the US, containing representative vaccine strains for both B-strain 
lineages, as well as the H1N1 and H3N2 A subtypes. 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 31 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
1.2
Rationale
The investigational product (aQIV) is an MF59-adjuvanted egg-derived subunit 
inactivated quadrivalent influenza virus vaccine. A 0.5 mL dose is formulated to contain 
15 mcg hemagglutinin (HA) of each influenza virus strain, including representative 
strains of both B lineages. The aQIV formulation is consistent with the currently licensed 
Fluad trivalent influenza virus vaccine (aTIV), but contains an additional B influenza 
strain so that the total HA concentration is 60 mcg HA/0.5 mL dose, from four strains.
The aim of this study is to demonstrate that inclusion of an additional B vaccine strain 
elicits an antibody response to that strain and does not adversely impact the 
immunogenicity response against strains previously included in trivalent formulations. 
Additionally, the aim is to demonstrate and confirm an acceptable safety and tolerability 
profile for the quadrivalent influenza vaccine formulation in the elderly population.
Data from this study will be used to support the licensure of aQIV for the prevention of 
seasonal influenza in adults ≥ 65 years of age.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 32 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
2.
OBJECTIVES
2.1
Primary Objectives
Co-Primary Immunogenicity Objectives:
1. To demonstrate that vaccination with aQIV elicits an immune response that is 
not inferior to that of an aTIV containing the same virus strains as the US 
licensed adjuvanted influenza vaccine (Fluad, aTIV-1), and an aTIV containing 
the alternate B strain (aTIV-2) among adults ≥65 years of age.
2. To assess the immunogenicity of aQIV in adults ≥65 years of age, based on the 
CBER (Center for Biologics Evaluation and Research) recommendations.
2.2
Secondary Immunogenicity Objectives
The secondary immunogenicity objectives of the study are to assess the following, 
among adults aged ≥ 65 years: 
1. To characterize the immunogenicity of aQIV, the aTIV-1 containing the same 
virus strains as the US licensed adjuvanted trivalent influenza vaccine, and the 
aTIV-2 containing the alternate B strain, by hemagglutination inhibition (HI).
2. To demonstrate the immunological superiority of aQIV compared to aTIV-1 and 
aTIV-2 for the B strain that is not included in each TIV vaccine separately.
2.3 
Secondary Safety Objective: 
1. To assess safety and tolerability of aQIV, aTIV-1, and aTIV-2 among adults ≥65 
years of age.
2.4
Exploratory Immunogenicity Objectives
1. To explore the association between HI immune response after administration of 
aQIV or the aTIV-1, containing the same virus strains as the US-licensed 
adjuvanted trivalent influenza vaccine, and the aTIV-2 containing the alternate 
B strain by baseline characteristics.
2. Additional optional objectives include characterization of the immunogenicity 
of aQIV using other immunological assays (e.g., virus neutralization [MN] or 
anti-neuraminidase antibody assays may be performed).
Both exploratory objectives may be performed using either homologous or heterologous 
strains, or both.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 33 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
3.
STUDY DESIGN
3.1
Overview of Study Design
This phase 3 study is a randomized, double-blinded, comparator controlled, parallel 
group, multicenter study of aQIV versus the US licensed 2017-2018 adjuvanted trivalent 
influenza vaccine (Fluad, aTIV-1), and versus an adjuvanted trivalent influenza vaccine, 
aTIV-2, containing the alternate B strain.
The study will be conducted during the 2017-2018 Northern Hemisphere influenza season 
in male and female adults aged 65 years and older who are healthy or have co-morbidities 
(Section 5.1.2) which increase their risk of complications from influenza infection. 
Subjects will be randomized to one of the three treatment groups in a 2:1:1 ratio. An 
Interactive Response Technology (IRT) system will be used for subject randomization.
Subjects will provide serological specimens before and after vaccination as well as 
complete Diary Cards for solicited local and systemic adverse events. 
Each subject will have two stages of study participation: Treatment Period (Day 1 through 
Day 22) and Follow-up Period (Day 23 through Day 181).
Treatment Period: Day 1 through Day 22
Written informed consent must be obtained prior to any study-related procedures. The 
informed consent process may be conducted up to 10 days before the day of vaccination 
(Day 1). Prior to vaccination on Day 1, evaluations will be performed and will include 
medical history, physical examination, and vital signs. A blood sample will be collected 
from all eligible subjects for influenza-specific serology testing. All eligibility 
assessments need to be completed prior to blood sample collection. Subjects will be 
assessed for risk of complications from influenza using the scoring system described by 
Hak (2004). 
All eligible subjects will then receive a dose of 0.5 mL of study vaccine to which they 
were assigned, administered intramuscularly in the deltoid muscle, preferably of the non-
dominant arm.
After vaccination, all subjects will remain under medical supervision at the study site for 
at least 30 minutes to be monitored and evaluated for local and systemic adverse events 
(AEs).
Subjects will receive a thermometer, a ruler and a Diary Card, along with instructions to 
ensure proper completion, and will note any occurrence of solicited local and systemic 
AEs, and record their oral temperatures for events occurring on Day 1 through Day 7. The 
Diary Card will only be used to collect solicited adverse events.
A reminder telephone call will be made on Day 3 (window, Day 2 to Day 4) to remind the 
subject to complete the Diary Card. 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 34 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
A scripted safety telephone call will be made by qualified site staff on Day 15 (window: 
Day 12 to day 18) to collect any unsolicited AEs and any use of concomitant medications: 
these will be captured in the electronic Case Report Form (CRF).
Subjects will return to the clinic on Day 22 (window, Day 19 to Day 25) for a medical 
examination, and to provide a blood sample for serologic testing. During this visit Diary 
Cards will be collected and all unsolicited AEs and concomitant medication use 
(occurring after vaccination between Day 1 and Day 22) will be documented in the 
subject’s source records and captured in the CRF.
Any subject who manifests signs of an influenza-like illness (ILI, defined as at least one 
of the following respiratory symptoms: sore throat, cough, sputum production, wheezing, 
or difficulty breathing; concurrently with at least one of the following systemic 
symptoms: temperature of >37.2°C/ 99°F, chills, tiredness, headache, or myalgia) during 
the may be performed at any time during the Treatment Period(Days 1-22) will be 
evaluated by real time reverse transcription polymerase chain reaction (RT-PCR) testing 
of a nasopharyngeal (NP) specimen for influenza. Swabs will be sent to a qualified central 
laboratory as specified in the Clinical Investigator Laboratory Manual. Subjects with 
onset of ILI and RT-PCR-confirmed influenza during the Treatment Period (Days 1-22) 
will be removed from the Per Protocol Set (PPS) in the immunogenicity analyses. ILI will 
also be recorded as an adverse event.
Follow-up Period: Day 23 through Day 181
A scripted safety telephone call will be made by qualified site staff on Day 91 (window: 
Day 84 to Day 98) to collect only those unsolicited AEs that are: serious AEs (SAEs), 
AEs leading to study withdrawal, new onset of chronic diseases (NOCDs), adverse events 
of special interest (AESIs); and concomitant medications associated with these events. 
A scripted safety telephone call will be made by qualified site staff on Day 181 (window: 
Day 167 to Day 195) for assessment of SAEs, AEs leading to study withdrawal, NOCDs, 
and AESIs; and concomitant medications associated with these events.
An unscheduled study visit may be performed as necessary for further evaluation of 
safety information that is described on the telephone that is to be investigated further at 
any time during the study.
A clinical study report will present immunogenicity and safety data collected through the 
final evaluation (6 months following vaccination, Day 181).
3.2
Study Period
Each subject should expect to participate in the study for approximately 6 months from 
the time of enrollment through the last study visit (Day 181 phone call).
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 35 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
3.3
Blinding Procedures
The trial is designed as a double-blind study. There are no visible differences between the 
investigational aQIV vaccine and the two comparator aTIV vaccines. Vaccines will be 
selected and administered according to the Pack ID assigned to the subjects by IRT. 
Neither the subject nor any of the investigative staff who are involved in administering 
the vaccines or clinical evaluation of the subject will be aware of the vaccine 
administered.
In case of an emergency, the Investigator can disclose the subject’s assigned vaccine. The 
information can be retrieved from the IRT system either via web or phone (a 24/7 backup 
service).
Except in the case of medical necessity, a subject’s treatment should not be unblinded 
without the approval of the Sponsor. In general, unblinding should only be performed 
when knowledge of the assigned treatment will affect a subject’s management. In such 
instance of medical emergency, every effort should be made to contact the Sponsor prior 
to unblinding. If unblinding should occur (by either accidental unblinding or emergency 
unblinding for an SAE) prior to completion of the study, the Investigator must promptly 
contact the Sponsor and document the circumstances on the appropriate forms. 
Instructions regarding emergency unblinding will be provided to the Investigator.
All personnel involved in performing laboratory assays and others who are directly 
involved in the conduct of the trial or in the analysis of the final trial results will remain 
blinded to the treatment codes until at least the database has been locked for final 
analysis.
3.4
Data Collection
3.4.1
Data Collected from Subjects
The following data will be collected from each subject over the duration of their study 
participation:

Medical History

Vaccination History 

Demographic Information.

All unsolicited AEs (from Day 1 through Day 22)

Adverse Events (from Day 23 through Day 181):
o
AEs leading to withdrawal
o
AESIs
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 36 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
o
NOCDs
o
SAEs
o
Concomitant Medications (as defined in Section 6.5)

Reason for study termination
All data collected must only be identified using the Subject ID, as described in Section 
5.1.4, Randomization.
3.4.2
Tools Used for Data Collection
Data will be recorded in the Diary Card and collected on Case Report Forms (CRFs).
Diary Cards
Subjects will be given a paper diary at their Day 1 clinic visit to complete. The paper 
diaries, hereafter referred to as the Diary Card, will be the only source document allowed 
for solicited local and systemic adverse events (including body temperature 
measurements), starting after the initial 30 minute postvaccination period at the clinic 
through Day 7.
At the Day 22 clinic visit subjects are to return their completed Diary Card and the site 
staff should review the information entered with them. The following additional rules 
apply to documentation of safety information collected in the Diary Card:
1. No corrections or additions to the information recorded by the subject or legal 
representative to the Diary Card will be allowed after it is delivered to the site.
2. Any blank or illegible fields on the Diary Card must be described as missing in the 
CRF.
Case Report Forms
This study utilizes electronic Case Report Forms (CRFs) to collect study-related data 
from each subject. A qualified site staff member(s) is required to enter subject data in the 
CRFs in English based on the medical information available in each subject’s source 
record.
Data should be entered into the CRF in a timely fashion following each subject’s clinic 
visit, study procedure, or phone call. Each subject’s CRF casebook will be compared with 
the subject’s source records by a Seqirus-approved study monitor (or designee) over the 
duration of the study in order to ensure data collection accuracy.
The following additional rules apply to documentation of Diary Card information 
collected in the CRFs:
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 37 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
1. The site must enter all readable entries in the Diary Card into the CRF, including 
those values that may be biologically implausible (e.g., body temperature: 400°C).
2. Any illegible or implausible data should be reviewed with the subject or legal 
representative. If an underlying solicited or unsolicited adverse event is described on 
review with the subject, this should be described in the source document and reported 
as an unsolicited adverse event in the Adverse Event CRF (e.g., if the subject above 
confirms body temperature of 40°C on the day in which body temperature: 400°C was 
written into his/her Diary Card, this fever of 40°C should be recorded in the Adverse 
Event CRF).
3. Any newly described safety information (including a solicited adverse event) must not 
be written into the Diary Card and must be described in the study file as a verbally 
reported adverse event. Any adverse event reported in this fashion must be described 
as an unsolicited adverse event and therefore entered on the Adverse Event CRF.
3.5
Collection of Clinical Specimens
The following clinical specimens are required to be collected from each subject in this 
study:

Blood at the Day 1 and Day 22 clinic visits

Nasopharyngeal swabs (as needed from subjects experiencing symptoms that meet ILI 
criteria from Day 1 through Day 22)
Collection and processing of each specimen should be completed by a qualified site
member and in accordance with the study-specific Clinical Specimen Laboratory Manual. 
Testing of clinical specimens will be performed by a Seqirus designated laboratory. Refer 
to the study-specific Clinical Specimen Laboratory Manual for additional details.
Blood Specimens
Approximately 10 mL sample of blood will be drawn from all eligible subjects at Day 1 
before vaccination and at Day 22. The blood volume will not exceed 10 mL at each time 
point in order to provide the necessary serum volume (approximately half of the blood 
draw volume) for the serology assays. See Section 7, Assessments for additional details.
The total amount of blood collected over the study period per subject will be 
approximately 20 mL.
Nasopharyngeal Swabs
Subjects, who from Day 1 to Day 22, experience symptoms meeting the ILI criteria (ie, at 
least one of the following respiratory symptoms [new onset or exacerbation of pre-
existing condition]: sore throat, cough, sputum production, wheezing, or difficulty 
breathing concurrently with at least one of the following systemic symptoms: temperature 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 38 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
of > 37.2°C/ 99°F, chills, tiredness, headache, or myalgia), will have one NP swab 
collected for evaluation of the presence of influenza virus by RT-PCR. The NP swab will 
be collected as soon as possible within 3 days of ILI onset, but collection up to 6 days will 
be permitted.
3.6
Stopping/Pausing Guidelines
There are no predetermined stopping rules in this study. Subjects may be withdrawn from 
the study according to investigator discretion as described in Section 3.8, Premature 
Withdrawal from Study.
The Sponsor can halt the study at any time. If the study is halted, the Sponsor will 
promptly notify the health authorities and investigators, who will promptly inform the 
study subjects and local Ethics Committee/ Institutional Review Board (EC/IRB) as per 
local regulations. Further enrollment will only occur after written authorization is 
provided by the Sponsor in consultation with the health authorities and EC/IRB, as 
appropriate.
3.7
Data Monitoring Committee
An independent Data Monitoring Committee will not be utilized for the study.
3.8
Premature Withdrawal from Study
Subjects may withdraw at any time, or be dropped from the study at the discretion of the 
investigator should any untoward effects occur and/or for safety reasons. In addition, a 
subject may be withdrawn by the investigator or the Sponsor if he/she violates the study 
plan or for administrative reasons. The Investigator or study coordinator must notify the 
Sponsor immediately when a subject has been withdrawn due to an adverse event.
The circumstances above are referred to as premature withdrawal from the study, and the 
reason for premature withdrawal should be clearly documented and detailed in the source 
documentation. The investigator should make every attempt to evaluate the subject’s 
safety, including resolution of ongoing AEs, at the time of premature withdrawal. If a 
subject wants to withdraw from the study prior to the last planned study visit, the subject 
will be asked to be followed for safety for the duration of the study. When a subject 
withdraws, or is withdrawn, from the study, the procedures described in Section 5.5.1, 
Early Termination Visit should be completed if possible. Withdrawn subjects will not be 
replaced.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 39 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
The reasons for premature withdrawal from the study include: Adverse event, death, 
withdrawal of consent, lost to follow-up, administrative reason, and protocol deviation. 
These reasons are described in greater detail below.
Adverse Event
For any subject withdrawn from study participation prior to the planned Study 
Termination Visit, it is important to determine if an AE was associated with the reason for 
discontinuing the study. This AE must be identified on the AE CRF page by indicating 
“Withdrawn from study due to AE”. Any ongoing AEs at the time of study withdrawal 
must be followed until resolution or stabilization (see Section 7.1, Safety Assessments).
Death
For any subject withdrawn from study participation due to death, this should be noted on 
the Study Termination CRF page and the associated SAE that led to the death must be 
reported (see Section 7.1, Safety Assessments).
Withdrawal of consent
The subject (or their legally appointed representative) can withdraw consent for 
participation in the study at any time without penalty or loss of benefit to which the 
subject is otherwise entitled. If the subject withdraws consent for the study, no further 
study procedures will be performed with the subject.
If a subject withdraws consent but does not revoke the Health Insurance Portability and 
Accountability Act (HIPAA) authorization, the Sponsor will have full access to the 
subject’s medical records, including termination visit information. If a subject revokes 
only the HIPAA authorization, the Sponsor will have full access to all of the subject’s 
medical records prior to the date and time of written revocation.
Lost to Follow-Up
For subjects who fail to show up for visits (clinic or telephone contacts), study staff are 
encouraged to make at least three documented attempts to contact the subject by 
telephone and at least one documented written attempt to contact the subject to encourage 
the completion of study termination procedures. These efforts to contact the subject 
should be recorded in the source document. The termination date for the subject to be 
captured on the Study Termination CRF page is the date of the last successful contact 
(clinic visit or telephone) with the subject.
Administrative Reason
Examples for subjects withdrawn from the study due to administrative reason can include: 
Sponsor decision to terminate the study, subject meeting a prespecified withdrawal 
criterion, subject discontinuation for insurance issues, moving, no time, etc. This reason 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 40 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
should be noted in the Study Termination CRF page and any ongoing AEs at the time of 
study withdrawal must be followed until resolution/stabilization whenever possible.
If the clinical study is prematurely terminated by the Sponsor, the investigator is to 
promptly inform the study subjects and local EC/IRB and should assure appropriate 
therapy and follow up for the subjects. All procedures and requirements pertaining to the 
archiving of study documents should be followed. All other study materials (study 
medication/vaccines, etc.) must be returned to the Sponsor.
Protocol Deviation
A protocol deviation is any change, divergence, or departure from the study design or 
procedures of a study protocol. In general, subjects associated with protocol deviations 
may remain in the study unless continuation in the study jeopardizes the subject’s health, 
safety, or rights.
Investigators will apply due diligence to avoid protocol deviations. Under no 
circumstances should the Investigator contact Seqirus or its agents, if any, monitoring the 
study to request approval of a protocol deviation, as no authorized deviations are 
permitted. If the Investigator feels a change to the protocol would improve the conduct of 
the study this must be considered a protocol amendment, and unless such an amendment 
is agreed upon by Seqirus and approved by the IRB/EC and health authorities it cannot be 
implemented. 
For subjects who are withdrawn from the study due to receipt of an excluded 
medication/vaccination or due to significant protocol non-compliance, this reason should 
be noted in the Study Termination CRF page.
3.9
End of Study
Evaluation of the primary and secondary immunogenicity objectives requires the testing 
of biological samples from the study subjects, which can only be completed after all 
samples are collected. The last samples for the analysis of the primary and secondary 
immunogenicity objectives will be taken at Day 22. For the purpose of this protocol, end 
of study is defined as the completion of the Last Subject Last Visit (LSLV), i.e. the last 
subject’s Day 181 safety phone call, or the completion of testing of biological samples, to 
be achieved no later than 8 months after LSLV, whichever is longer.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 41 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
4.
SELECTION OF STUDY POPULATION
4.1
Inclusion Criteria
Subjects must meet all of the following inclusion criteria to participate in this study:
1. Males and females ≥ 65 years old who are healthy or have co-morbidities
2. Individuals who or whose legal representative(s) have voluntarily given written 
consent after the nature of the study has been explained according to local 
regulatory requirements, prior to study entry
3. Ability to attend all scheduled visits and to comply with study procedures 
including Diary Card completion and follow-up (and responding to messages and 
telephone contact). A subject or legal representative should be considered able to 
comply if the Investigator judges that the subject will complete the Diary Card 
when applicable, return for all the follow-up visits, and be available for telephone 
calls as scheduled in the study
4.2
Exclusion Criteria
If one or more of the following exclusion criteria are met, the subject will be ineligible to 
take part in this study:
1. History of behavioral or cognitive impairment or psychiatric condition that, in the 
opinion of the Investigator, may interfere with the subject's ability to participate in
the study
2. History of any medical condition considered an adverse event of special interest
3. Progressive or severe neurological disorder, seizure disorder, or history of 
Guillain-Barré syndrome
4. Hypersensitivity, including allergy, to any component of vaccines, medicinal 
products or medical equipment whose use is foreseen in this study
5. Clinical conditions representing a contraindication to intramuscular vaccination 
and blood draws, including bleeding diathesis, or any other condition that may be 
associated with prolonged bleeding
6. Abnormal function of the immune system resulting from: 
a. Clinical conditions affecting the immune system (e.g. HIV infection,
  agammaglobulinemia)
b. Systemic administration of corticosteroids (PO/IV/IM) at a dose 
equivalent to 20 mg/day of prednisone for more than 14 consecutive days 
within 90 days prior to informed consent
c. Administration of antineoplastic and immunomodulating agents (eg,
TNF α- antagonists or anti-B cell antibodies) or radiotherapy within 1 year
prior to informed consent
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 42 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
7. Receipt of immunoglobulins or any blood products within 180 days prior to 
informed consent
8. Receipt of an investigational or nonregistered medicinal product within 30 days 
prior to informed consent or before completion of the safety follow-up period in 
another study, or who are unwilling to refuse participation in another clinical 
study at any time during the conduct of this study (note: concomitant participation 
in an observational study not involving drugs, vaccines, or medical devices, is 
acceptable)
9. Study personnel or immediate family members (brother, sister, child, parent), the 
spouse of personnel with direct involvement in the study
10. Receipt of any influenza vaccine within 6 months prior to enrollment in this study,
or plan to receive influenza vaccine prior to the Day 22 blood collection
11. Receipt of any inactivated non-influenza vaccine 14 days or live-attenuated 
vaccine 28 days prior to enrollment in this study or plans to receive any other non-
influenza vaccine within 28 days from study vaccination
12. Fever at the time of screening, defined as oral temperature ≥38.0 degrees Celsius 
(≥100.4° F). Enrollment could be considered if fever is absent for 72 hours
13. Signs or symptoms of acute infection at the time of screening. Enrollment could 
be deferred if signs and symptoms are absent for 72 hours
14. Fatal prognosis of an underlying medical condition (<12 months life expectancy)
15. Any other clinical condition that, in the opinion of the Investigator, might interfere 
with the results of the study or pose additional risk to the subject due to 
participation in the study
4.3
Criteria for Delay of Vaccination
There may be instances when individuals meet all eligibility criteria for vaccination yet 
have a transient clinical circumstance which may warrant delay of vaccination: body 
temperature elevation [≥38.0°C (≥ 100.4° F) within 3 days prior to intended study 
vaccination], or use of antipyretics and/or analgesic medications within 24 hours prior to 
vaccination. Under such circumstances, a subject may be considered eligible for study 
enrollment after the appropriate window for delay has passed and inclusion/exclusion 
criteria have been rechecked, and if the subject is confirmed to be eligible.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 43 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
5.
STUDY PROCEDURES
The sections that follow provide an overview of the procedures that are to be followed in 
enrolling, evaluating, and following subjects who participate in this clinical study. Visits 
can be either clinic visits or safety follow-up telephone calls, as specified in the Table 
below and in the Time and Events Table.
Table 5
Study Procedures
Visit Category
Procedures
Prevaccination Clinic Visit
Section 5.1 describes procedures to be followed 
prior to study vaccination: informed consent, 
screening, enrollment, and randomization
Vaccination Clinic Visit
Section 5.2 describes procedures to be followed 
during the vaccination clinic visit: vaccination, post-
vaccination procedures, and post-vaccination 
reminder call
Postvaccination Visit/Call(s) 
Section 5.3 describes follow-up clinic visits and 
safety follow-up calls
Unscheduled Visit(s)
Section 5.4 describes possible procedures to be 
followed at unscheduled clinic visit
Study Termination Visit
Section 5.5 describes procedures to be followed at 
the last study visit for a subject (may include early 
termination visit)
5.1
Prevaccination Clinic Visit(s)
This section describes the procedures that must be performed for each potential subject 
prior to vaccination, including obtaining informed consent, screening, enrollment and 
randomization.
5.1.1
Informed Consent
"Informed consent" is the voluntary agreement of an individual or his/her legal 
representative(s) to participate in research. Consent must be given with free will of 
choice, and without undue inducement. The individual must have sufficient knowledge 
and understanding of the nature of the proposed research, the anticipated risks and 
potential benefits, and the requirements of the research to be able to make an informed 
decision.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 44 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Informed consent of the subject following local IRB/EC guidance must be obtained 
before conducting any study-specific procedures (i.e., all of the procedures described in 
the protocol). The process of obtaining informed consent should be documented in the 
subject source document in addition to maintaining a copy of the signed and dated 
informed consent. Additional specifics regarding the informed consent and assent 
processes are located in Section 13.2, Informed Consent Procedures.
If a subject is unable to read, an impartial witness should be present during the entire 
informed consent discussion. An impartial witness is defined as a person who is 
independent from study conduct, who cannot be unfairly influenced by those involved 
with the study, who attends the informed consent process if the subject or the subject's 
legally acceptable representative cannot read, and who reads the informed consent form 
and any other written information supplied to the subject. After the written informed 
consent form and any other written information to be provided to subjects, is read and 
explained to the subject or legal representative and after the subject or legal representative
has verbally consented to the subject’s participation in the study and, if capable of doing 
so, has signed and personally dated the informed consent form, the witness should sign 
and personally date the consent form. By signing the consent form, the witness attests that 
the information in the consent form and any other written information was accurately 
explained to, and apparently understood by, the subject or legal representative and that 
informed consent was freely given by the subject or legal representative. 
5.1.2
Screening
After an individual has consented to participate in the study and informed consent is 
signed, that individual will be given a unique Screening Number manually created by the 
Investigator. The subject’s unique Screening Number will be documented in the 
Screening and Enrollment log. The eligibility of the subject will be determined based on 
the inclusion and exclusion criteria listed in Section 4, Selection of Study Population and 
evaluated during this screening procedure.
Prior to study enrollment, demographic data will be collected from the subject, including: 
age, sex, race, ethnicity, height and weight, prior influenza vaccination, comorbidity, and 
risk of complications from influenza indicated by a calculated score. The risk assessment 
which incorporates medical comorbidity among other baseline characteristics is a 
validated predictor of risk of complications from influenza in subjects ≥65 years of age 
(Hak, 2004) (see Table 5.1.2-1, Prediction Rule for Estimating the Probability of 
Hospitalization Due to Pneumonia or Influenza and Death Due to Any Cause). Using this 
model, a score of <50 is considered low risk and a score of ≥ 50 is considered high risk.
Determination of pre-existing medical conditions, for the purpose of calculating the risk 
score, should be made by the investigator based on his or her clinical judgment. A list of 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 45 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
medical conditions are presented in Appendix 1 as examples for the Investigator to 
facilitate the completion of the co-morbidity section of the risk score.
Table 5.1.2-1:         Prediction Rule for Estimating the Probability of Hospitalization 
Due to Pneumonia or Influenza and Death Due to Any Cause (Hak 2004)
Characteristic
Scorea
Age, years
<70
0
70-74
14
75-79
28
80-89
42
≥90
56
Sex
Female
0
Male
9
Outpatient visits during the previous yearb
0
0
1-6
11
7-12
22
>13
33
Previous hospitalization due to pneumonia or influenza
No
0
Yes
63
Comorbidityc
Pulmonary disease
18
Heart disease
6
Renal disease or renal transplant
12
Dementia or stroke
22
Non-hematological and hematological cancer
48
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 46 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Notes: a The prognostic score for a given subject can be obtained by adding the scores for each applicable 
characteristic. b Scheduled and unscheduled face-to-face visits with a physician or other health-care 
providers, including annual examinations, or visits to urgent care and emergency departments c Pre-existing
medical conditions of eligible subjects will be scored following judgment by the Investigator. Appendix 1
provides a list of conditions with examples to provide guidance to the Investigator.
Only the total risk score will be recorded in the CRF; pre-existing medical conditions 
should be recorded in the source documentation. The risk score will be collected for each 
subject, but will not be used to stratify treatment. 
Medical history will be collected, including but not limited to any medical history that 
may be relevant to subject eligibility for study participation such as prior vaccinations, 
concomitant medications, and previous and ongoing illnesses or injuries. Relevant 
medical history can also include any medical history that contributes to the understanding 
of the risk score and of an adverse event that occurs during study participation, if it 
represents an exacerbation of an underlying disease/pre-existing problem.
Review of systems is a structured interview that queries the subject or legal representative
as to any complaints the subject has experienced across each organ system. This will be 
performed before enrollment and used to guide physical examination.
If applicable, prior and concomitant medications or vaccinations taken prior to start of 
study should be collected (refer to Section 6.5, Prior and Concomitant Medications and 
Vaccines for further details).
Collection of vital signs is to be performed: heart rate, blood pressure, respiratory rate and 
prevaccination body temperature (preferably oral). If body temperature is ≥38.0°C (or 
≥100.4°F) at the time of screening, vaccination must be postponed until 3 days after the 
fever has resolved (see Section 4.3, Criteria for Delay of Vaccination).
Measure height and weight. Measurement and recording of vital signs, height, weight and 
body temperature, must be conducted by a trained health care professional.
A general physical examination is to be performed by a qualified health care practitioner. 
“Qualified health care practitioner” refers to any licensed health care professional who is 
permitted by institutional policy to perform physical examinations and who is identified 
within the Study Staff Signature Log.
The data described above will be written in the source document (see Section 9.1, Source 
Documentation). Should the physical assessment reveal any abnormal values or events, 
these must be documented as part of medical history.
Prior to vaccination, approximately 10 mL of blood will be drawn from all subjects for 
immunogenicity testing (see Section 3.5, Collection of Clinical Specimens).
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 47 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
In the event that the individual is determined ineligible for study participation, he/she is 
considered a screen failure. The reason for screen failure must be documented in the 
Screening and Enrollment log. If the individual is determined to be eligible for the study, 
he/she will be enrolled into the study.
5.1.3
Enrollment
After signing the informed consent form, if an individual is determined to be eligible for 
study participation, the investigator or delegate will enroll the subject and enter subject 
information into the Interactive Response Technology (IRT) system.
5.1.4
Randomization
Enrolled subjects will be randomized in the IRT system and automatically assigned a 
unique Subject ID. The Subject ID will be the subject’s unique identification number for 
all CRFs and associated study documentation that will be used for duration of the study. 
After randomization, the Screening Number ceases to be used and remains in the 
Screening and Enrollment Log only. The list of randomization assignments is produced 
by the IRT service provider and approved by Seqirus or delegate.
Subjects will be randomized in a 2:1:1 ratio to aQIV, aTIV-1, and aTIV-2. 
If for any reason, after signing the informed consent form (ICF), the subject who is 
eligible and enrolled fails to be randomized, this is called a randomization failure. Further 
guidance is provided in the CRF Instructions. The reason for all randomization failures 
should be recorded in the Screening and Enrollment Log and in the source document as 
specified in the Source Data Agreement (SDA). The information on subjects who are 
randomization failures should be kept distinct from subjects who are screen failures, as 
described in Section 5.1.2, Screening.
If for any reason, after randomization the subject fails to undergo treatment, this is an 
Early Termination and the reason should be recorded in source document as specified in 
the SDA. The information on these Early Termination subjects should be kept distinct in 
the source documentation from randomization failures.
5.2
Vaccination Clinic Visit(s)
Please refer to Time and Events Table 2. Vaccination will be performed on Day 1 using 
the vaccine identified by the assigned Pack ID. The Day 1 serology sample must be taken 
prior to vaccination.
After completing the prevaccination procedures as described in Section 5.1,
Prevaccination Clinic Visit(s), the vaccine will be administered to the subject according to 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 48 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
the procedures described in Section 6.3, Vaccine Preparation and Administration. Prior to 
administration of each vaccination, it should be confirmed that the subject is eligible for 
vaccination and does not meet any criteria for delaying study vaccination as described in 
Section 4, Selection of Study Population.
5.2.1
Postvaccination Procedures
The following postvaccination procedures will be performed on Day 1.   
Observation Period
After vaccination, the subject will be observed for at least 30 minutes for unsolicited 
adverse events, solicited adverse events, and a body temperature measurement (preferably 
oral) will be taken. During this observation period, the subject should be trained on how 
to use the thermometer and the ruler provided, how to measure local solicited adverse 
events, and how to report systemic solicited events (see Section 7.1.1, Solicited Adverse 
Events). All safety data collected during this time should be recorded in the subject’s 
source document.
Diary Card Training
A Diary Card will be used in this study to document solicited adverse events from Day 1 
to Day 7. The Diary Card is the only source for collection of these data; therefore, it is 
critical that the subject completes the Diary Card correctly. The subject should be trained 
on how and when to complete each field of the Diary Card. The Diary Card should be 
completed on a daily basis, preferably in the evening, and the entries should be written 
clearly in pen. See additional rules in Section 3.4.2, Tools Used for Data Collection.
The subject or legal representative should be trained on how to self-measure local 
solicited adverse events and body temperature. The measurement of solicited local 
adverse events is to be performed using the ruler provided by the site.
The subject or legal representative should be instructed how to perform body temperature 
measurement using the thermometer provided by the site. Temperature should be checked 
at least daily; if the subject feels unusually hot or cold during the day, the subject or legal 
representative should make additional measurement of body temperature. If the subject 
has fever, the highest body temperature observed that day should be recorded in the Diary
Card.
Diary Card training should be directed at the individual(s) who will perform the 
measurements of adverse events and who will enter the information into the Diary Card. 
In some situations, the Diary Card may be completed by somebody other than the subject 
or legal representative (except study site personnel). If a person other than the subject or 
legal representative enters information into the Diary Card, the reason that the subject 
cannot complete their own Diary Card and the person’s identity and relationship to the 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 49 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
subject must be documented in the Diary Card. Any individual that makes entries into the
Diary Card must receive training on completion of the Diary Card at the time of the visit. 
This training must be documented in the subject’s source.
The same individual should complete the Diary Card throughout the course of the study.
Plan Next Study Activities
The site should schedule the next study activity with the subject or legal representative. It 
is recommended for the site to already schedule in advance the remaining upcoming study 
activities.
Discharge
The subject or legal representative should be reminded to contact the site if there are any 
questions, and to contact the site immediately (or as soon as the subject is medically 
stable) if the subject has a medical condition that leads to a hospitalization or an 
emergency room visit or to a visit to/by a doctor or is otherwise of concern.
The subject or legal representative will be reminded to contact the site immediately if the 
subject experiences symptoms meeting ILI criteria in order to have a NP swab collected 
for evaluation of the presence of influenza virus. If anti-viral medications (eg, 
neuraminidase inhibitors) are prescribed it is recommended that an NP swab be obtained 
prior to the first dose.
5.2.2
Postvaccination Reminder Call
Reminder calls are not intended to be an interview for collection of safety data. If the 
subject wishes to describe safety information, this information should only be collected 
by a qualified healthcare professional at the site, and the safety data described must be 
written down in the subject’s source documentation and CRF.
Diary Card Day 3 Reminder Phone Call
Subjects will receive a diary reminder call on Day 3. The purpose of this call is to remind 
the subject or legal representative about completion of the Diary Card. The call follows 
the Diary Card Reminder Phone Call Script provided to the site. The subject or legal 
representative should be reminded to contact the site via the telephone number provided 
in the informed consent to discuss medical questions.
5.3
Postvaccination Clinic Visit and Safety Calls
A postvaccination clinic visit will be performed on Day 22. Postvaccination Safety Calls 
will be performed on Day 15, Day 91, and Day 181.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 50 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
5.3.1
Follow-up Clinic Visit
At the clinic visit on Day 22, the Diary Card will be reviewed and collected. No changes 
to the information recorded within the Diary Card are permissible. For details on the 
Diary Card see Section 3.4.2, Tools Used for Data Collection and Section 
5.2.1, Postvaccination Procedures. The subject or legal representative will be interviewed 
to determine if any unsolicited adverse events (including SAEs, ILIs, NOCDs, AEs 
leading to withdrawal and AESIs) occurred and if any concomitant medications or 
vaccines were taken/received during the time since the last clinic visit. This interview will 
follow a script which will facilitate the collection of relevant safety information. The 
qualified healthcare professional reviewing these data will discuss the symptoms (if any) 
reported by the subject and will determine if any additional diagnoses and/or adverse 
events are present. All adverse events reported by the subject or legal representative at 
this follow-up clinic visit must be recorded in the subject's source document and on an 
Adverse Events CRF, as specified in Section 7.1, Safety Assessment, and not written on 
the script used for the interview.
During the Day 22 clinic visit, the subject will be asked whether he or she was 
hospitalized or was evaluated at an emergency room or a physician’s office for any illness 
since the site’s last contact with the subject. If an SAE has been identified by the site staff 
during the interview which has not previously been reported by the subject, this SAE will 
be reported by the site within 24 hours to Seqirus or delegate. Any additional relevant 
medical history will be recorded as needed.
During the Day 22 clinic visit, an ILI assessment will be performed to determine if 
symptoms of ILI are present. Potential ILI symptoms will be documented in the subject’s 
source records. If the onset of the ILI is 6 days or less before the visit, a NP swab should 
be collected from the subject for influenza testing and study staff will document the ILI 
on an Adverse Event and ILI CRF (see procedures described in Section 5.4, Unscheduled 
Visits).
During the Day 22 clinic visit, a brief symptom-directed physical examination will be 
performed by a qualified health care practitioner according to symptoms the subject has 
reported. This physical examination will include an examination of organ systems that are 
considered relevant by the investigator based on review of the subject’s reported adverse 
events, and concomitant medication use. This assessment may include measurement of 
vital signs (respiratory rate, blood pressure and heart rate), body temperature (preferably 
oral) and a check of general appearance. The physical assessment must be performed by 
the investigator or designee of the investigator, who is qualified to perform a physical 
assessment in accordance with their institutional policy. Measurement and recording of 
vital signs and body temperature may be conducted by a trained health care professional. 
Corresponding information is documented in the subject’s source document and CRF(s).
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 51 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
During the Day 22 follow-up clinic visit, approximately 10 ml of blood will be drawn 
(see Section 3.5, Collection of Clinical Specimens).
The site should also schedule the next study activity, the Day 91 safety call, with the 
subject. It is recommended for the site to also schedule in the remaining upcoming study 
activities whenever possible.
At the Day 22 follow-up clinic visit, the subject will receive a written reminder of the 
next planned study activity. The subject or legal representative will be reminded to 
contact the site immediately (or as soon as the subject is medically stable) if the subject 
has a medical condition that leads to a hospitalization, or is otherwise of concern.
5.3.2
Safety Follow-up Phone Calls
Safety follow-up calls will be performed on Day 15, Day 91, and Day 181.
Safety follow-up calls are calls made to the subject by a qualified healthcare professional 
designated on the site delegation log. These calls will follow a script which will facilitate 
the collection of relevant safety information. The subject will be interviewed according to 
the script.
On Day 15, information will be collected regarding all unsolicited adverse events and 
concomitant medications or vaccinations associated with those events. Safety follow-up 
calls performed on Days 91 and 181 will collect information relating to a subset of 
unsolicited adverse events including SAEs, adverse events of special interest (AESIs), 
AEs leading to withdrawal, new onset of chronic disease (NOCD), and concomitant 
medications or vaccinations associated with those events. All safety information 
described by the subject must be written down in a designated location within the source 
document and not written on the script used for the telephone call.
The subject will be asked as to whether he or she was hospitalized or was evaluated at an 
emergency room for any illness since the site’s last contact with the subject. If an SAE 
has been identified by the site staff during the interview which has not previously been 
reported by the subject, this SAE will be reported by the site within 24 hours to Seqirus or 
delegate. Any additional relevant medical history will be reported to Seqirus or delegate 
and recorded as needed.
On Day 15, if the subject reports during the phone contact that symptoms are present 
consistent with an ILI, the subject will be asked to visit the site for further evaluation and 
potential NP swab taking. An NP swab should be collected, for evaluation of the presence 
of influenza virus, preferably within 3, but up to 6, days after the first day of onset of ILI 
symptoms. See procedures described in Section 5.4, Unscheduled Visits.
On Day 15, the subject will be reminded to contact the site immediately if the subject 
experiences symptoms meeting ILI criteria to have a NP swab collected for evaluation of 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 52 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
the presence of influenza virus. If anti-viral medications (e.g., neuraminidase inhibitors) 
are prescribed it is recommended that an NP swab be obtained prior to the first dose.
The subject will receive a reminder of the next planned study activity. The subject will be 
reminded to contact the site immediately (or as soon as the subject is medically stable) if 
the subject has a medical condition that leads to a hospitalization or an emergency room 
visit or to a visit to/by a doctor or is otherwise of concern.
5.4
Unscheduled Visits
An unscheduled visit describes a non-routine study visit triggered by a specific event. 
These could include anticipated or unanticipated adverse events or interventions.
5.4.1 Subjects Meeting Influenza-Like-Illness Criteria
Clinic Visit – Obtaining NP Swab
Subjects will be asked to come to the site for an unscheduled clinic visit when 
experiencing symptoms meeting the ILI criteria from Day 1 through Day 22. The visit 
should occur as soon as possible within 3, but up to 6, days after the first day of onset of 
ILI symptoms. During the visit the following procedures should be carried out:

Assess ILI symptoms and record associated medication. Document any anti-viral 
medication use from the first day of onset of ILI symptoms

Collect a NP swab for evaluation of the presence of influenza virus following the 
procedures for collecting, processing and shipping as described in the Lab Manual

Evaluate the subject’s body temperature (preferably oral), heart rate, respiratory rate 
and blood pressure and perform a symptom-directed physical examination

Record the ILI and related information, in the source documents and in the CRF (ILI-
report and adverse events section)

Schedule next study activity
5.5
Study Termination Phone Call 
The study termination visit (call) will occur on Day 181. The termination visit will be a 
telephone call. The date of termination is the date of the last contact (clinic visit or 
telephone call) in which the subject’s health status was assessed or, in cases where the 
subject does not agree to any further safety follow-up, it is the date consent is withdrawn. 
This date should be recorded on the termination CRF page. For visit procedures to be 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 53 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
performed for a subject whose planned study participation ends prematurely, please see 
Section 5.5.1, Early Termination Visit.
The termination telephone call will collect information relating to a subset of unsolicited 
adverse events including SAEs, adverse events of special interest (AESIs), AEs leading to 
withdrawal, new onset of chronic disease (NOCD), and concomitant medications or 
vaccinations associated with those events. All safety information described by the subject 
must be written down in a designated location within the source document and not written 
on the script used for the telephone call.
The subject will be asked as to whether he or she was hospitalized or was evaluated at an 
emergency room for any illness since the site’s last contact with the subject. If an SAE 
has been identified by the site staff during the interview which has not previously been 
reported by the subject, this SAE will be reported by the site within 24 hours to Seqirus or 
delegate. Any additional relevant medical history will be reported to Seqirus or delegate 
and recorded as needed.
The site will complete the termination CRF page and this will mark the completion of the 
subject’s participation in the study.
5.5.1
Early Termination Visit
When a subject is withdrawn from treatment or withdraws from the study, the 
Investigator will notify the Sponsor and, when possible, will perform the procedures 
listed below. The reason(s) for the early termination will be included in the subject’s 
source documentation. If the Early Termination Visit is a telephone call, collect as much 
information as possible. Early Termination Visits include subjects who were randomized 
but not treated.
At the clinic visit or during the telephone call, the same procedures will be performed as 
during the study termination visit, see Section 5.5 Study Termination Visit, if possible. 
In addition, the following procedures will be performed:

Collect and review the Diary Card, if applicable

Review the subject’s safety data (if collection of these was in progress at the time of 
study termination)
The site will complete the termination CRF page and this will mark the completion of the 
subject’s participation in the study.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 54 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
6.
TREATMENT OF SUBJECTS
All vaccines associated with this study are to be stored separately from other vaccines and 
medications in a secure location under appropriate storage conditions with temperature 
monitoring. All vaccines associated with this study must be checked for expiration 
date prior to use. Expired vaccines must not be administered to subjects.
6.1
Study Vaccines
The term ‘study vaccine’ refers to those vaccines provided by the Sponsor, which will be 
evaluated as part of the study objectives. The study vaccines specific to this study are 
described below. All three influenza vaccines are made similarly, with the exception of 
the influenza strains included.
Investigational Vaccine: aQIV
An approximately 0.5 mL dose of aQIV (quadrivalent MF59C.1 adjuvanted influenza 
vaccine) contains nominally 15 mcg of hemagglutinin (HA) of each of the 2 influenza 
type A strains and each of the 2 influenza type B strains for a total of 60 mcg of HA in the 
vaccine. The strain composition is that recommended by the World Health Organization
for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent 
vaccines. The full composition of the vaccine is reported in Table 6.1-1.
Table 6.1-1:           aQIV Vaccine Composition
Names of Ingredients
Quantity per dose*
Function
Active  Ingredients
Hemagglutinin (HA) and neuraminidase (NA) 
antigens from the influenza virus strains 
recommended by WHO for the manufacture of 
influenza vaccine for 2017-2018 season
A/ Michigan/45/2015 (H1N1) 
A/ Hong Kong/4801/2014 (H3N2)
B/ Phuket/3073/2013 (Yamagata lineage)
B/ Brisbane/60/2008 (Victoria lineage)
nominally 15mcg
HA/strain
Active ingredient
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 55 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Names of Ingredients
Quantity per dose*
Function
Adjuvant 
Squalene 
Polysorbate 80
Sorbitan trioleate
Sodium citrate
Citric acid
9.75mg
1.175mg
1.175mg
0.66mg
0.04mg
Oil phase
Surfactant 
Surfactant
Buffer
Buffer
Other Ingredients 
Sodium chloride 
Potassium chloride
Potassium dihydrogen phosphate
Disodium phosphate dehydrate
Magnesium chloride hexahydrate 
Calcium chloride dihydrate
Water for injection
4.00mg
0.10mg
0.10mg
0.67mg
0.05mg
0.06mg
up to 0.50mL
Isotonic aid 
Buffer 
Buffer
Buffer 
Stabiliser 
Stabiliser
Diluent
**
Volume of Formulation
0.5 mL
Appearance
Liquid, milky-white emulsion
Vaccine Presentation
Prefilled syringe
*  the quantities indicated in this table reflect the amount in a 0.5 mL dose.
** residues of special relevance: barium sulfate, cetyltrimethylammonium bromide (CTAB), chicken
  proteins, such as ovalbumin, formaldehyde, kanamycin and neomycin sulfate.
US-licensed Comparator Vaccine: Fluad, aTIV-1
An approximately 0.5 mL dose of aTIV-1 (trivalent MF59C.1 adjuvanted influenza 
vaccine) contains nominally 15 mcg of hemagglutinin (HA) of each of the 2 influenza 
type A strains and one influenza type B strain for a total of 45 mcg of HA in the vaccine. 
The strain composition is that recommended by the World Health Organization for the 
2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines. 
The full composition of the vaccine is reported in Table 6.1-2.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 56 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Table 6.1-2:           aTIV-1 Vaccine Composition
Names of Ingredients
Quantity per dose*
Function
Active  Ingredients
Hemagglutinin (HA) and neuraminidase (NA) 
antigens from the influenza virus strains 
recommended by WHO for the manufacture of 
influenza vaccine for 2017-2018 season
A/ Michigan/45/2015 (H1N1) 
A/ Hong Kong/4801/2014 (H3N2)
B/ Brisbane/60/2008 (Victoria lineage)
nominally 15mcg
HA/strain
Active ingredient
Adjuvant 
Squalene 
Polysorbate 80
Sorbitan trioleate
Sodium citrate
Citric acid
9.75mg
1.175mg
1.175mg
0.66mg
0.04mg
oil phase
Surfactant 
Surfactant
Buffer
Buffer
Other Ingredients 
Sodium chloride 
Potassium chloride
Potassium dihydrogen phosphate
Disodium phosphate dehydrate
Magnesium chloride hexahydrate 
Calcium chloride dihydrate
Water for injection
4.00mg
0.10mg
0.10mg
0.67mg
0.05mg
0.06mg
up to 0.50mL
Isotonic aid 
Buffer 
Buffer
Buffer 
Stabiliser 
Stabiliser
Diluent
**
Volume of Formulation
0.5 mL
Appearance
Liquid, milky-white emulsion
Vaccine Presentation
Prefilled syringe
*  the quantities indicated in this table reflect the amount in a 0.5 mL dose.
** residues of special relevance: barium sulfate, cetyltrimethylammonium bromide (CTAB), chicken   
     proteins, such as ovalbumin, formaldehyde, kanamycin and neomycin sulfate.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 57 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Comparator Vaccine Containing the Alternate B strain: aTIV-2
An approximately 0.5 mL dose of aTIV-2 (a trivalent MF59C.1 adjuvanted influenza 
vaccine) contains nominally 15 mcg of hemagglutinin (HA) of each of the 2 influenza 
type A strains and one influenza type B strain for a total of 45 mcg of HA in the vaccine. 
The strain composition is that recommended by the World Health Organization for the 
2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines. 
for the A strains, but the one B strain included in this vaccine is the second influenza B 
strain recommended for inclusion in quadrivalent vaccines (ie, the alternate B strain). The 
full composition of the vaccine is reported in Table 6.1-3.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 58 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Table 6.1-3:           aTIV-2 Vaccine Composition
Names of Ingredients
Quantity per dose*
Function
Active  Ingredients
Hemagglutinin (HA) and neuraminidase (NA) 
antigens from the influenza virus strains
recommended by WHO for the manufacture of 
influenza vaccine for 2017-2018 season
A/ Michigan/45/2015 (H1N1) 
A/ Hong Kong/4801/2014 (H3N2)
B/ Phuket/3073/2013 (Yamagata lineage)
nominally 15mcg
HA/strain
Active ingredient
Adjuvant 
Squalene 
Polysorbate 80
Sorbitan trioleate
Sodium citrate
Citric acid
9.75mg
1.175mg
1.175mg
0.66mg
0.04mg
oil phase
Surfactant 
Surfactant
Buffer
Buffer
Other Ingredients 
Sodium chloride 
Potassium chloride
Potassium dihydrogen phosphate
Disodium phosphate dehydrate
Magnesium chloride hexahydrate 
Calcium chloride dihydrate
Water for injection
4.00mg
0.10mg
0.10mg
0.67mg
0.05mg
0.06mg
up to 0.50mL
Isotonic aid 
Buffer 
Buffer
Buffer 
Stabiliser 
Stabiliser
Diluent
**
Volume of Formulation
0.5 mL
Appearance
Liquid, milky-white emulsion
Vaccine Presentation
Prefilled syringe
*  the quantities indicated in this table reflect the amount in a 0.5 mL dose
**  residues of special relevance: barium sulfate, cetyltrimethylammonium bromide (CTAB), chicken   
      proteins, such as ovalbumin, formaldehyde, kanamycin and neomycin sulfate
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 59 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
6.2
Non-Study Vaccines
Not applicable.
6.3
Vaccine Preparation and Administration
The Investigator or designee will be responsible for oversight of the administration of 
vaccine to subjects enrolled in the study according to the procedures stipulated in this 
study protocol and the Pharmacy Manual. All vaccines will be administered only by 
personnel who are qualified to perform that function under applicable local laws and 
regulations for the specific study site.
Detailed vaccine preparation and administration instructions will be provided to 
investigators prior to study start.
PRECAUTIONS TO BE OBSERVED IN ADMINISTERING STUDY VACCINE:
Prior to vaccination, subjects must be determined to be eligible for study vaccination and 
it must be clinically appropriate in the judgment of the Investigator to vaccinate. 
Eligibility for vaccination prior to first study vaccine administration is determined by 
evaluating the entry criteria outlined in protocol Section 4.1, Inclusion Criteria and 
Section 4.2, Exclusion Criteria.
Eligibility for study vaccination is determined by following the criteria outlined in 
Section 4.3, Criteria for Delay of Vaccination.
Study vaccines should not be administered to individuals with known hypersensitivity to 
any component of the vaccines.
Standard immunization practices are to be observed and care should be taken to 
administer the injection intramuscularly. Before administering vaccine, the vaccination 
site is to be disinfected with a skin disinfectant (e.g., 70% alcohol). Allow the skin to dry. 
DO NOT inject intravascularly or intragluteally.
As with all injectable vaccines, trained medical personnel and appropriate medical 
treatment should be readily available in case of anaphylactic reactions following vaccine 
administration. For example, epinephrine 1:1000, diphenhydramine, and/or other 
medications for treating anaphylaxis should be available.
6.4
Vaccine Administration Error or Overdose of Vaccine
Vaccine administration error is defined as receiving a dose of study vaccine that was not 
reconstituted as instructed or administered by a different route from the intended route of 
administration. An overdose of study vaccine (whether accidental or intentional) is 
defined when a dosage higher than the recommended dosage is administered in one dose 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 60 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
of study vaccine. An administration error includes underdosing, where an incomplete 
dose of vaccine is given, caused by mechanical failure or other reason. 
An overdose would also occur if two doses of the study vaccine are administered within 
half the time of the recommended interval between doses, as defined in the protocol.
Any vaccine administration error or overdose of study vaccine detailed in this protocol 
must be reported as an adverse event, and if the vaccine administration error or overdose 
is associated with a serious adverse event, it must be reported as such within 24 hours to 
the Sponsor or delegate.
6.5
Prior and Concomitant Medications and Vaccines
All influenza vaccination history in the 5 years prior to subject enrollment into the study 
is to be obtained from the subject and recorded in the subject’s source records. All 
influenza vaccinations received by the subject in the 12 months prior to enrollment (or for 
the 2016 – 2017 flu season) into the study should additionally be recorded on the Prior 
and Concomitant Medications CRF.
All medications and vaccines taken or received by the subject within 2 months prior to the 
start of the study are to be recorded on the Prior and Concomitant Medications CRF. Any 
blood products received within 3 months prior to enrollment must also be documented in 
the Prior and Concomitant Medications CRF. Vitamins and minerals are excluded from 
this scope.
The use of antipyretics and/or analgesic medications within 24 hours prior to vaccination 
must be identified and the reason for their use (prophylaxis versus treatment) must be 
described in the source document and Concomitant Medications CRF. The use of 
antipyretics/analgesics within 24 hours prior to vaccine administration is a reason to delay 
study vaccination (see Section 4.3, Criteria for Delay of Vaccination). The use of low-
dose aspirin for cardiovascular prophylaxis is not considered effective analgesic therapy 
and is thus allowed. 
Medications taken for prophylaxis are those intended to prevent the onset of symptoms. 
Medications taken for treatment are intended to reduce or eliminate the presence of 
symptoms that are present.
Concomitant medications include all medications (including vaccines) taken 
by/administered to the subject at and after enrollment.
Administration of any other influenza vaccine, seasonal or pandemic, is prohibited until 
after collection of the follow-up serology on Day 22.
The following concomitant medications will be recorded in the Concomitant Medications 
CRF:
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 61 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015

All concomitant medications from Day 1 to Day 22

All medications associated with SAEs, NOCD, AESIs, and AEs that lead to premature 
withdrawal from the study, from Day 1 to study termination

All vaccines, including any seasonal or pandemic influenza vaccines, from Day 1 to 
Day 181
When recording concomitant medications/vaccines, they should be checked against the 
study entry and continuation criteria in Section 4, Selection of Study Population to ensure 
that the subject should be enrolled/continue in the study.
Use of the following concomitant medications after enrollment and prior to the Day 22 
blood collection should be documented on the Concomitant Medication CRF page as they 
may have an effect on the interpretation of the study objectives and therefore may be 
determined to be a reason for exclusion from one of the analysis sets.

Anti-viral medication following ILI, prior to obtaining a NP swab

Blood, blood products or a parenteral immunoglobulin preparation

Oral or systemic corticosteroids (topical, inhaled, intranasal corticosteroids are
permitted)

Other immunosuppressive agents
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 62 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
6.6
Vaccine Supply, Labeling, Storage and Tracking
The Sponsor will ensure the following:

Supply the study vaccines

Appropriate labeling of all study vaccines provided that complies with the legal 
requirements of each country where the study is to be performed
The Investigator must ensure the following:

Acknowledge receipt of the study vaccines by a designated staff member at the site, 
including:
o
Confirmation that the vaccines were received in good condition
o
Confirmation to the Sponsor of the temperature range during shipment from the 
Sponsor to the Investigator’s designated storage location
o
Confirmation by the Sponsor that the vaccines are authorized for use

Proper storage of the study vaccines, including:
o
Storage in a secure, locked, temperature-controlled location
o
Proper storage according to the instructions specified on the labels
o
Appropriate record keeping and inventory of the study vaccines, including regular 
documentation of adequate storage temperature

Appropriate use of the study vaccines, including:
o
No use of vaccines prior to receipt of authorization for use from the Sponsor
o
Use only in accordance with the approved protocol
o
Proper handling, including confirmation that the vaccine has not expired prior to 
administration
o
Appropriate documentation of administration of vaccines to study subjects 
including:
▪
Date, dosage, batch/lot numbers, expiration dates, unique identifying numbers 
assigned to subjects and study vaccines, and time of vaccine administration. 
This information will be maintained in an accountability log that will be 
reviewed by the site monitor
▪
Reconciliation of all vaccines received from the Sponsor. Reconciliation is 
defined as maintaining records of which and how many vaccines were 
received, which vaccines were administered to subjects, which vaccines were 
destroyed at the site, and which vaccines were returned to the Sponsor, as 
applicable
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 63 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015

Proper adherence to the local institutional policy with respect to destruction of study 
vaccines

Complete record keeping of vaccine use, wastage, return or destruction, including 
documentation of:
o
Copy of the site’s procedure for destruction of hazardous material
o
Number of doses destroyed, date of destruction, destruction code (if available), 
method of destruction, and name of individual performing destruction
Vaccines that have been stored differently from the manufacturer’s indications must not
be used unless the Sponsor provides written authorization for use. In the event that the use 
cannot be authorized, the Sponsor will make every effort to replace the vaccine supply. 
All vaccines used in conjunction with this protocol must be stored separately from normal 
hospital/practice stocks to prevent unintentional use of study vaccines outside of the 
clinical study setting.
Monitoring of vaccine accountability will be performed by the study monitor during site 
visits and at the completion of the study.
At the conclusion of the study, and as appropriate during the course of the study, the 
investigator must ensure that all unused study vaccines, packaging and supplementary 
labels are destroyed locally (upon approval from Sponsor) or returned to the Sponsor.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 64 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
7.
ASSESSMENTS
7.1
Safety Assessment
The measures of safety used in this study are routine clinical procedures. They include a 
close vigilance for, and stringent reporting of, selected local and systemic adverse events 
routinely monitored in vaccine clinical studies as indicators of reactogenicity.
An adverse event (AE) is defined as any untoward medical occurrence in a subject or 
clinical investigation subject administered a pharmaceutical product at any dose that does 
not necessarily have to have a causal relationship with this treatment. Therefore, an AE 
can be any unfavorable and unintended sign (including an abnormal laboratory finding, 
for example), symptom, or disease temporally associated with the use of an 
investigational product, whether or not considered related to the investigational product. 
This definition includes intercurrent illnesses or injuries and exacerbation of pre-existing 
conditions.
The period of observation for AEs extends from the time the subject signs informed 
consent until he or she completes the specified safety follow-up period or terminates the 
study early (whichever comes first). AEs occurring after the informed consent form is 
signed but prior to receiving study vaccine/product will be documented as an adverse 
event and recorded within source document. However, any AEs occurring prior to receipt 
of any study vaccine will be listed separately from “treatment emergent” AEs (AEs 
occurring after administration of the first study vaccine).
Adverse events are collected as either solicited or unsolicited adverse events. Solicited 
events are derived from organized data collection systems, such as Subject Diaries or 
interview.
7.1.1
Solicited Adverse Events
The term “reactogenicity” refers to solicited signs and symptoms (“solicited adverse 
events”) occurring in the hours and days following a vaccination, to be collected by the 
subject or legal representative(s) for 7 consecutive days, using a predefined Diary Card.
The following solicited adverse events are included in the Diary Card. Each adverse event 
is to be assessed using the scoring system reported in parentheses below: 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 65 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Solicited Local Adverse Events
Induration, erythema and ecchymosis will be measured by the subject and recorded 
directly on the Diary Card.
Injection site pain will be measured as follows: grade 0= absent, grade 1/mild= present 
but does not interfere with activity, grade 2/moderate = interferes with activity, grade 
3/severe = prevents daily activity.
Solicited Systemic Adverse Events
Loss of appetite will be measured as follows: grade 0 = none, grade 1/mild = eating less 
than usual with no effect on normal activity, grade 2/moderate = eating less than usual / 
interfered with normal activity, grade 3/severe = not eating at all.
Nausea will be measured as follows: grade 0 = none, grade 1/mild = no interference with 
daily activity, grade 2/moderate = interferes with daily activity, grade 3/severe = prevents 
daily activity.
Fatigue, generalized myalgia, generalized arthralgia, headache and chills will be 
measured using the following scoring system: grade 0 = none, grade 1/mild= no 
interference with daily activity, grade 2/moderate = interferes with daily activity, grade 
3/severe = prevents daily activity.
Vomiting will be measured as follows: grade 0 = none, grade 1/mild = 1-2 times per 24 
hours, grade 2/moderate = 3 to 5 times per 24 hours, grade 3/severe = 6 or more times in 
24 hours or requires intravenous hydration.
Diarrhea will be measured as follows: grade 0 = fewer than 2 loose stools per 24 hours, 
grade 1/mild = 2-3 loose stools in 24 hours, grade 2/moderate = 4-5 stools in 24 hours, 
grade 3/severe = 6 or more loose stools in 24 hours or requires intravenous hydration.
Other Solicited Adverse Events

Use of analgesics/antipyretics will be captured as “absent” or “present” and will also 
be summarized by “for treatment” or “for prophylaxis”;

Body temperature will be captured. Fever is defined as body temperature 
≥38.0°C/100.4°F, as measured preferably orally.
The study staff must review the data entered into the Diary Card as described in Section 
3.4.2, Tools Used for Data Collection and Section 5.3.1, Follow-up Clinic Visit(s).
Note: Any solicited adverse event that meets any of the following criteria must be entered 
into subjects’ source document (see Section 9.1, Source Documentation) and also as an 
adverse event on the Adverse Event CRF:

Solicited local or systemic adverse event that continues beyond Day 7 after 
vaccination
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 66 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015

Solicited local or systemic adverse event that leads to a visit to a healthcare provider 
(medically attended adverse event, see Section 7.1.3, Evaluation of Adverse Events)

Solicited local or systemic adverse event leading to the subject withdrawing from the 
study or the subject being withdrawn from the study by the investigator (adverse event 
leading to withdrawal, see Section 7.1.3, Evaluation of Adverse Events)

Solicited local or systemic adverse event that otherwise meets the definition of a 
serious adverse event (see Section 7.1.4, Serious Adverse Events)
7.1.2
Unsolicited Adverse Events
An unsolicited adverse event is an adverse event that was not solicited using a Diary Card 
and that was spontaneously communicated by a subject or legal representative(s) who has 
signed the informed consent.
All unsolicited adverse events, and medications used to treat them, will be collected from 
study admission (at the time of informed consent) through the Day 22 clinic visit. After 
the day 22 visit, only unsolicited adverse events, and medication used to treat them, which 
meet criteria for the following will be collected: serious adverse events, adverse events of 
special interest, new onset of chronic disease, and events leading to study discontinuation. 
7.1.3
Evaluation of Adverse Events
Every effort should be made by the Investigator to evaluate safety information reported 
by a subject for an underlying diagnosis and to capture this diagnosis as the event in the 
AE page. In other words, the practice of reporting only symptoms (e.g., “cough” or “ear 
pain”) are better reported according to the underlying cause (e.g., “asthma exacerbation” 
or “otitis media”).
The severity of events reported on the Adverse Events CRF will be determined by the 
Investigator as:
Mild:
transient with no limitation in normal daily activity.
Moderate:
some limitation in normal daily activity.
Severe:
unable to perform normal daily activity.
The relationship of the study treatment to an AE will be determined by the Investigator 
based on the following definitions:
1. Not Related
The AE is not related to an investigational vaccine if there is evidence that clearly 
indicates an alternative explanation. If the subject has not received the vaccine, the timing 
of the exposure to the vaccine and the onset of the AE are not reasonably related in time, 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 67 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
or other facts, evidence or arguments exist that reasonably suggest an alternative 
explanation, then the AE is not related.
2. Possibly Related
The administration of the investigational vaccine and AE are considered reasonably 
related in time and the AE could be explained by exposure to the investigational vaccine 
or by other causes.
3. Probably Related
Exposure to the investigational vaccine and AE are reasonably related in time and no 
alternative explanation has been identified.
The relationship of the study treatment to an unsolicited AE will be determined by the 
Investigator. 
Note: solicited AEs will not be evaluated for relationship to study treatment. Grading for 
severity of solicited local and systemic AEs is described in Section 7.1.1, Solicited 
Adverse Events.
Adverse events will also be evaluated by the Investigator for the coexistence of any of the 
other following conditions:

AESI see Section 7.1.4.1, AESI

“New onset of chronic disease” (NOCD): an adverse event that is a new diagnosis of a 
chronic medical condition that was not present or suspected prior to study enrollment

AEs leading to withdrawal: adverse events leading to study withdrawal
If solicited or unsolicited adverse events have been reported and the subject or legal 
representative(s) indicated that the symptoms required medical attendance or were of 
concern, the subject or legal representative(s) must be contacted for further information.
When the subject or legal representative(s) is contacted for any of these reasons, the 
contact must be documented in the subject’s source documentation.
All AEs, regardless of severity, will be monitored until resolution or until the Investigator 
assesses them as chronic or stable. All subjects experiencing AEs - whether considered 
associated with the use of the study vaccine or not - must be monitored until symptoms 
subside and any abnormal laboratory values have returned to baseline, or until there is a 
satisfactory explanation for the changes observed, or until death, in which case a full 
pathologist’s report should be supplied, if possible. The Investigator’s assessment of 
ongoing AEs at the time of each subject’s last visit should be documented in the subject’s 
medical chart.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 68 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
7.1.4
Serious Adverse Events
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any 
dose results in one or more of the following:

Death

Is life-threatening (i.e. the subject was, in the opinion of the Investigator, at immediate 
risk of death from the event as it occurred); it does not refer to an event which 
hypothetically might have caused death if it were more severe

Required or prolonged hospitalization

Persistent or significant disability/incapacity (ie, the event causes a substantial 
disruption of a person’s ability to conduct normal life functions)

Congenital anomaly/or birth defect

An important and significant medical event that may not be immediately life 
threatening or resulting in death or hospitalization but, based upon appropriate 
medical judgment, may jeopardize the subject or may require intervention to prevent 
one of the other outcomes listed above
Adverse events which do not fall into these categories are defined as non-serious.
It should be noted that a severe adverse event need not be serious in nature and that a 
serious adverse event need not, by definition, be severe.
All SAEs will be evaluated by the Investigator for relationship of the event to study 
vaccine. SAEs that are judged to be possibly or probably related to the study vaccine 
should be reported  as related/suspected events.  
The relationship of the study treatment to an SAE will be determined by the Investigator 
based on the following definitions:
1. Related/suspected
The SAE is judged by the Investigator to be possibly or probably related to the study 
vaccine on the AE CRF page (see Section 7.1.3, Evaluation of Adverse Events).
2. Not Related
The SAE is not related if exposure to the study vaccine has not occurred, or the 
occurrence of the SAE is not reasonably related in time, or the SAE is considered 
unlikely to be related to use of the study vaccine, i.e. there are no facts (evidence) or 
arguments to suggest a causal relationship.
The relationship of the study vaccine to an SAE will be determined by the Investigator.
SAEs will be evaluated by Seqirus or its designee for “expectedness.” An unexpected AE 
is one that is not listed in the current Summary of Product Characteristics or the 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 69 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Investigator’s Brochure or an event that is by nature more specific or more severe than a 
listed event.
Any pre-existing event or condition that results in hospitalization should be recorded on 
the Medical History CRF. If the onset of an event occurred before the subject entered the 
study (eg, any pre-planned hospitalization for conditions like cosmetic treatments or for 
non-emergency routine visits for a pre-existing condition), the hospitalization would not 
lead to an AE being classified as serious unless, in the view of the Investigator, 
hospitalization was prolonged as a result of participation in the clinical study or was 
necessary due to a worsening of the pre-existing condition.
7.1.5
Adverse Events of Special Interest
The Investigator will be provided with a list of AESIs prior to FSFV. Receipt of this list 
will be documented and stored, along with the list of AESIs in the Investigator Study File. 
During the course of the trial the list of AESIs may change. If this occurs the investigators 
will be advised of the change and confirmation of receipt will be documented. The 
updated list of AESIs and documentation of receipt are also stored in the Investigator 
Study File.
Subjects will be assessed at each visit for any new medical events or signs or symptoms 
that could possibly indicate an AESI. The subject will be asked whether any new 
diagnosis has been given to the subject through a review of recent medical history. Should 
a qualified health care practitioner who is not the Investigator suspect a potential AESI, 
she/he should promptly inform the Investigator. The AESI diagnosis will be recorded in 
the medical chart/source document as well as in EDC along with any medication used to 
treat the condition.
Onset of an AESI is to be reported to Seqirus or its designee via EDC in the same manner 
and time frame as an SAE (see Section 7.1.6 and SAE/AESI Reporting Plan). 
All AESIs will be reviewed for signal evaluation by Seqirus or its designee and assessed 
for expedited reporting.
7.1.6
Methods for Recording and Reporting Adverse Events and Serious Adverse 
Events
Findings regarding adverse events must be reported on an Adverse Events CRF, as 
specified in Section 7.1.1, Solicited Adverse Events. All findings in subjects experiencing 
AEs must also be reported in the subject's source document.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 70 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
All SAEs and AESIs which occur during the course of the study, whether considered to 
be associated with the study vaccination or not, must be reported within 24 hours of the 
site becoming aware of the event to Seqirus or its designee via EDC. If entry into EDC
is not possible (eg, because the system is non-functional), the paper SAE/AESI Form 
must be completed and submitted via facsimile/email to Seqirus or its designee. Refer to 
SAE/AESI Reporting Plan for specific instructions and contact details for collecting and 
reporting SAEs.
Any medication or other therapeutic measures used to treat the AE will be recorded on the 
appropriate CRF(s) in addition to the outcome of the AE.
After receipt of the initial reporting, representatives of Seqirus or its designee will contact 
the Investigator if it is necessary to obtain further information for assessment of the event.
All SAEs must be reported by the Investigator to his/her corresponding EC /IRB or   
applicable regulatory authorities in accordance with institutional policy/regulatory 
requirements, and adequate documentation of this notification must be provided to the 
Sponsor.
Seqirus or its designee must also comply with the applicable regulatory requirement(s) 
related to the reporting of suspected unexpected serious adverse vaccine reactions (also 
known as SUSARs) to the regulatory authority(ies) and the IRB/EC. If a SUSAR or other 
safety signal relating to use of one of the study vaccines is reported to Seqirus or its 
designee, the Sponsor will communicate the information to the Investigator and the 
Investigator will be responsible for submitting this information to the EC/IRB and other 
relevant authorities.
7.1.6.1
Post-Study Events
Any SAE that occurs outside of the protocol-specified follow-up period and considered to 
be caused by the study vaccine must be reported to Seqirus or its designee. There is no 
time limit on reporting for SAEs related to study vaccine. Instructions and contact details 
for collecting and reporting these suspected SAEs will be provided to the Investigator.
7.1.7
Pregnancies
Not applicable for this study.
7.1.8
Safety Laboratory Measurements
No scheduled safety laboratory measurements are planned for this study.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 71 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
7.2
Efficacy Assessment
Not applicable.
7.3
Immunogenicity Assessment
The measure of immunogenicity used in this study, hemagglutination inhibition (HI) is 
widely accepted and generally recognized as reliable, accurate, and relevant (able to 
describe the quality and extent of the immune response).
The immunogenicity analyses will evaluate immunogenicity of aQIV and the comparator 
aTIVs measured by the HI assay by titrating antibodies against homologous or 
heterologous influenza strains. Homologous strains are antigenically similar to the strains 
in the vaccine and heterologous are antigenically distinct (CDC, 2014).
Additional immunologic assays, including microneutralization, may be used to measure 
neutralizing antibodies. 
Testing will be conducted by Seqirus designated qualified laboratory personnel blinded to 
the treatment assignment and the visit. Please see the Protocol Ancillary Document for 
name(s) and details.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 72 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
8.
STATISTICAL CONSIDERATIONS
8.1
Endpoints
8.1.1     Primary Endpoints
8.1.1.1
Co-Primary Immunogenicity Endpoints
The immunogenicity of study vaccines will be assessed 21 (i.e., on Day 22) days after 
vaccine administration by measuring the hemagglutination inhibition (HI) antibody titers 
to the four virus strains included in the vaccines.
The noninferiority of aQIV compared to aTIV-1, and to aTIV-2 will be assessed for the 
eight co-primary endpoints of HI geometric mean titer (GMT) and seroconversion rate 
(SCR) for each virus strain included in the vaccines as follows:

The GMT ratio* for the A/H1N1 strain

The GMT ratio for the A/H3N2 strain

The GMT ratio for the B strain (Yamagata lineage)

The GMT ratio for the B strain (Victoria lineage)

The difference between the SCR**for the A/H1N1 strain

The difference between the SCR for the A/H3N2 strain

The difference between the SCR for the B strain (Yamagata lineage)

The difference between the SCR for the B strain (Victoria lineage)
Immunogenicity results obtained from aTIV-1 and aTIV-2 for both A/H1N1 and A/H3N2 
strains will be pooled for comparison with aQIV.
*The GMT ratio is defined as the geometric mean of the post-vaccination (Day 22) HI 
titer for aTIV-1 (or aTIV-2) over the geometric mean of postvaccination (Day 22) HI titer 
for aQIV.
**The SCR is defined as the percentage of subjects with either a prevaccination HI titer 
< 1:10 and a post-vaccination HI titer ≥ 1: 40 or a prevaccination HI titer ≥ 1:10 and a ≥ 
4-fold increase in postvaccination HI titer.
The second co-primary immunogenicity objective for aQIV will be assessed 21 days after 
vaccine administration by applying CBER criteria for the elderly population for each of 
the 4 strains included in aQIV:

The percent of subjects achieving seroconversion for HI antibody
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 73 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015

The percent of subjects achieving an HI antibody titer ≥ 1:40
The study is considered successful if the (16) co-primary endpoints are achieved.
8.1.2
Secondary Immunogenicity Endpoints

The measures of immunogenicity of aQIV, aTIV-1 and aTIV-2 used for 
Secondary objective 1 as determined by the HI assay against homologous strains 
at Day 1 and 22 (unless indicated otherwise), include the following:

GMT: Geometric mean of HI titers on Day 1 and Day 22

Geometric mean ratio (GMR)*: The geometric mean of the fold increase of 
post- vaccination HI titer over the pre-vaccination HI titer (Day 22/Day 1)

The percentage of subjects with a titer ≥40 at Day 1 and Day 22

SCR: the percentage of subjects with either a prevaccination HI titer < 1:10 
and a postvaccination HI titer ≥ 1:40 or a prevaccination titer ≥ 1:10 and a ≥ 4-
fold increase in postvaccination titer on Day 22

For Secondary objective 2, the immunologic superiority of HI antibody responses 
for the alternate B strain (the influenza B strain included in the aQIV but not in the 
aTIV formulation) in aQIV will be assessed for each aTIV separately, using the
endpoints of the ratio of HI GMT and the difference of SCR for each B virus 
strain 21 days after vaccination.
8.1.3
Secondary Safety Endpoints
Safety and tolerability will be assessed by the frequency and severity of:

Solicited local and systemic adverse events (AEs) for 7 days following 
vaccination (Day 1 through Day 7)

All unsolicited AEs for 21 days following vaccination (Day 1 through Day 22) 
and medication associated with these events

Serious AEs (SAEs), AEs leading to withdrawal from the study, new onset of 
chronic diseases (NOCDs), AEs of special interest (AESIs), and concomitant 
medications associated with these events as collected from Day 1 through Day 
181
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 74 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
8.1.4
Exploratory Immunogenicity Endpoints

Exploratory immunogenicity endpoints include:

GMTs: Geometric mean HI titers (GMTs) at Day 1 and Day 22

SCRs: Percentage of subjects with either a prevaccination HI titer < 1:10 and a 
postvaccination HI titer ≥ 1:40, or a prevaccination titer ≥ 1:10 and a ≥ 4-fold 
increase in postvaccination titer at Day 22.

In case of any additional optional immunogenicity analyses, such as MN, or 
assessments using heterologous influenza strains, the immune response will be 
characterized in a similar manner as described in the secondary immunogenicity 
endpoints section above.
Further details regarding the endpoints and analyses of these assays will be described in 
the Statistical Analysis Plan (SAP) prior to unblinding.
8.2
Success Criteria
The study is considered successful if the co-primary objectives are achieved.
8.2.1
Success Criteria for Co-Primary Endpoints
8.2.1.1
To demonstrate noninferiority
In line with the FDA Guidance on seasonal inactivated influenza vaccines (Guidance for 
Industry Clinical Data Needed to Support Licensure of Seasonal Inactivated Influenza 
Vaccines 2007), aQIV will be considered to be noninferior to aTIV-1, containing the 
same virus strains as the US licensed adjuvanted trivalent influenza vaccine, and aTIV-2, 
containing the alternate B strain if, for each of the four strains, the following statistical 
criteria are met:

The upper bound of the two-sided 95% confidence interval (CI) for the ratio of the 
GMTs does not exceed 1.5. The GMT ratio will be calculated as GMT aTIV/GMT 
aQIV; and

The upper bound of the two-sided 95% CI for the difference between the SCRs 
does not exceed 10%. The difference in SCRs will be calculated as
Seroconversion aTIV–Seroconversion aQIV
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 75 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
8.2.1.2
CBER criteria for Co-Primary Endpoints:
The endpoints for percent of subjects vaccinated with aQIV achieving seroconversion and 
HI titer ≥ 1:40 at Day 22 will be assessed against the criteria described in CBER 
Guidance Clinical Data Needed to Support the Licensure of Seasonal Inactivated 
Influenza Vaccines (FDA, 2007):

The lower bound of the two-sided 95% confidence interval for the percentage of 
subjects achieving seroconversion for HI antibody should meet or exceed 30%

The lower bound of the two-sided 95% confidence interval for the percentage of 
subjects achieving an HI antibody titer ≥ 1:40 should meet or exceed 60%
The statistical evaluation consists of the observed proportion together with the 
corresponding two-sided 95% CI per strain. No adjustment for type I error for multiplicity 
is made.
No adjustment for type I error for multiplicity will be made. The study is successful if the 
co-primary immunogenicity objectives are achieved.
8.2.2
      Success Criteria for Secondary Objectives
8.2.2.1
Success Criteria for Secondary Immunogenicity Endpoints
There are no specific success criteria for the assessment of immunoassay results (first 
secondary objective).
Superiority of aQIV versus aTIV-1 and aTIV-2 for the alternate B strain will be assessed 
using the GMT ratio (GMTaTIV/GMTaQIV) and difference in SCR (SCR aTIV – SCRaQIV) at 
Day 22. Point estimates and two-sided 95% CIs will be obtained as described for the 
primary endpoint. Superiority will be declared if the upper limit of the two-sided 95% CI 
for the difference in SCRaTIV – SCRaQIV) is < 0%, and the upper limit of the two-sided 
95% CI for the GMT ratio (GMTaTIV / GMTaQIV) is < 1 for both B strains.
8.3
Description of Analysis Sets
There will be four analysis populations defined for the study analyses. These are defined 
in more detail in the SAP.
8.3.1
All Enrolled Set
All screened subjects who provide informed consent, receive subject ID, and provide
demographic and/or baseline screening information, regardless of the subject’s 
randomization and treatment status in the study.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 76 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
8.3.2 Full Analysis Set
All subjects in the All Enrolled Set who are randomized and receive a study vaccination. 
The FAS will be used to produce summaries and listings of subject characteristics.
8.3.3
Safety Set
The Safety Set will comprise all subjects in the FAS who received at least one dose or 
partial dose of Study Vaccine and have provided any evaluable follow-up safety data. The 
safety set will be used to produce summaries and listings of all safety data.
8.3.4
Evaluable Set – Immunogenicity Analysis
The Evaluable Set for immunogenicity analyses will comprise all subjects in the FAS 
who:

receive vaccine on Day 1

provide serology specimens which yield valid serology assay results from both Day 1 
and Day 22

do not experience a laboratory-confirmed influenza illness between Day 1 and Day 
22, and

do not receive any prohibited medication during the study that is medically assessed 
to potentially impact immunogenicity results
8.3.5
Per-Protocol Set
The Per-Protocol Set (PPS) will comprise all subjects in the Evaluable Set who do not 
have any protocol deviations that are medically assessed as potentially impacting on 
immunogenicity results.  
The Per Protocol Set will be the primary population of interest for the primary/secondary 
immunogenicity analysis and a supporting analysis will be performed using the Evaluable 
Set. Membership of the PPS will be determined prior to unblinding the study.
Duplicate tables of primary and secondary immunogenicity analyses may also be
produced based on the Evaluable population if there is >1% difference in the total number 
of subjects between the Per-Protocol Population and the Evaluable Population. The 
decision to produce tables based on the Evaluable Population will be made by Seqirus 
after population sets are finalised and prior to unblinding.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 77 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Examples for subjects excluded due to other reasons than protocol deviations are subjects 
who withdrew informed consent.
In case of misrandomization with regard to treatment arm, the subject is excluded from 
the PPS.
If a subject is unblinded during the study, except for SUSAR, he/she will be excluded 
from the PPS.
8.3.6
Subgroups
The immunogenicity analysis at Day 22 will be performed by stratifying for the following 
subgroups:

Age at enrollment (≥65-74, ≥75-84, and ≥85 years)

Sex

Race

Previous influenza vaccination in the past 5 years (yes/no)

Comorbidity/risk (yes/no, defined as assessment score < 50 or ≥50 based on scale 
described in Section 5.1.2) (Hak, 2004)
Safety analysis of any unsolicited adverse events and of any local, any systemic, or any 
other solicited adverse events (all adverse events combined for each such category) will 
be performed by stratifying for the following subgroups: 

Age at enrollment (≥65-74, ≥75-84, and ≥85years)

Sex

Race
8.3.7
Protocol Deviations
A protocol deviation is any change, divergence, or departure from the study design or 
procedures of a study protocol. A protocol deviation may be a reason to remove data from 
an analysis set at the time of analysis. Major protocol deviations will be defined as 
exclusionary from the analysis according to protocol objectives and endpoints, which will 
be specified in the statistical analysis plan. In some cases, exclusion of data may be due to 
a reason other than a protocol deviation, e.g. early termination.
Any deviation that affects the subject's rights, safety, or well- being and/or the
completeness, accuracy and reliability of the study data constitutes a major protocol
deviation. Changes or alterations in the conduct of the trial which do not have a major
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 78 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
impact on the subject's rights, safety or well-being, or the completeness, accuracy and
reliability of the study data are not considered major protocol deviations. All deviations 
will be reviewed to determine the final list of deviations that will be used for exclusion 
from the analysis set(s). This will be defined in the statistical analysis plan prior to 
unblinding.
All protocol deviations will be classified into those which are major and those which are 
not.  Major protocol deviations will be summarized by vaccine, center (overall) and 
grouped into the different categories as defined above. The site monitor will keep the 
investigator informed of all protocol deviations, so that the investigator can comply with 
reporting these deviations to the local EC/IRB according to their institutional policy.
Prior to unblinding, designated staff at the Sponsor will develop a memo that describes
the selected deviations that are identified as exclusions from analysis populations. This
memo will be included in the trial master file.
8.4
Statistical Analysis Plan
A complete description of the statistical analyses and methods will be available in the 
Statistical Analysis Plan (SAP), which will be finalized prior to unblinding.
8.4.1
Analysis of Demographic and Baseline Characteristics
Descriptive statistics (mean, standard deviation, median, minimum and maximum) for
age, height, weight, BMI, and comorbidity score at enrollment will be calculated overall 
and by vaccine groups.
Distributions of subjects by sex, ethnic origin (race, ethnicity), and previous vaccination 
status will be summarized overall, and by vaccine group.
8.4.1.1
Concomitant Medications
Use of concomitant medication will be presented by treatment, age cohort, therapeutic 
area, and preferred drug name.
Concomitant medications are all medications taken during the study period, including 
those started before but ongoing at vaccination.
If a start date for a medication is partially or fully missing, and it is unclear as to whether 
the medication is prior or concomitant, it will be assumed that it is concomitant.
Medications will be coded using the WHO Drug dictionary.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 79 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
8.4.2
Analysis of Primary Objective(s)
8.4.2.1
Analysis of Primary Efficacy Objective(s)
Not Applicable.
8.4.2.2
Analysis of Co-Primary Immunogenicity Objectives
The co-primary immunogenicity objectives are:
1. To demonstrate that vaccination with aQIV elicits an immune response that is 
not inferior to that of an aTIV containing the same virus strains as the US 
licensed adjuvanted influenza vaccine (Fluad, aTIV-1), and an aTIV containing 
the alternate B strain (aTIV-2) among adults ≥65 years of age
2. To assess the immunogenicity of aQIV in adults ≥65 years of age, based on 
CBER (Center for Biologics Evaluation and Research) criteria
8.4.2.2.1
Statistical Hypotheses
Noninferiority of aQIV to aTIV-1 and aTIV-2
To demonstrate that vaccination with aQIV elicits an immune response that is not inferior 
to that of an aTIV containing the same virus strains as the US licensed adjuvanted 
influenza vaccine (Fluad, aTIV-1), and an aTIV containing the alternate B strain (aTIV-2) 
among adults ≥65 years of age. according to the FDA Guidance on seasonal inactivated 
influenza vaccines (Guidance for Industry Clinical Data Needed to Support Licensure of 
Seasonal Inactivated Influenza Vaccines 2007). 
aQIV will be considered to be noninferior to aTIV if, for each of the four strains, the 
following statistical criteria are met: 

The upper bound of the two-sided 95% CI for the ratio of the GMTs does not 
exceed 1.5. The GMT ratio will be calculated by GMTaTIV/ GMTaQIV

The upper bound of the two-sided 95% CI for the difference between the SCRs 
does not exceed 10%. The difference in SCR will be calculated by SCRaTIV –
SCRaQIV
In mathematical notation, the statistical hypotheses to be tested for the primary 
immunogenicity analysis correspond to: 
H0: GMTri > 1.5, for any strain 
Ha: GMTri ≤ 1.5, for all strain 
and 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 80 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
H0: Di > 10, for any strain 
Ha: Di ≤ 10, for all strain 
where GMTri is any of the 4 strain-specific post immunogenicity dose GMT ratios 
namely,

GMTaTIV-1/ GMTaQIV for B/Yamagata strain 

GMTaTIV-2/ GMTaQIV for B/Victoria strain 

Pooled GMT(aTIV-1 and aTIV-2) /GMTaQIV for A/H1N1 strain 

Pooled GMT(aTIV-1 and aTIV-2) /GMTaQIV for A/H3N2 strain 
and Di is the 4 strain-specific post dose SCRs (πaTIV-1, πaTIV-2, πaQIV) difference, namely,
πaTIV-1 – πaQIV for B/Yamagata strain 
πaTIV-2 – πaQIV for B/Victoria strain 
Pooled π(aTIV-1 and aTIV-2)-πaQIV for A/H1N1 strain 
Pooled π(aTIV-1 and aTIV-2)-πaQIV for A/H3N2 strain 
where πv denotes the seroconversion rates for the vth vaccine (aQIV, aTIV-1, aTIV-2).
CBER Immunogenicity Criteria
The endpoints of percent of subjects achieving seroconversion and HI titer ≥ 1:40 at
Day 22 will be assessed against the criteria described in CBER Guidance Clinical Data
Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines (FDA, 
2007):

The lower bound of the two-sided exact 95% CI for the percentage of subjects 
achieving seroconversion for HI antibody should meet or exceed 30% and

The lower bound of the two-sided exact 95% CI for the percentage of subjects 
achieving an HI antibody titer ≥1:40 should meet or exceed 60%
Assuming that Yjk ~ B(1, πk), Zjk ~ B(1, τk), j=1,..,n, identical and independent Bernoulli 
distributed random variables with πk representing the unknown SC proportion 
postvaccination and τk representing the unknown SP (seroprotection, titer > 1:40)
proportion postvaccination in aQIV for strain k, where k denotes the 4 strains contained in 
aQIV vaccines, CBER requirements for the aQIV vaccine group translate into following 
hypothesis
H0k
(SC): πk ≤ 0.3
vs
H1k
(SC): πk > 0.3
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 81 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
H0k
(SP): τk ≤ 0.6
vs
H1k
(SP): τk > 0.6
All hypotheses related to CBER criteria will be tested on unadjusted 5% significance
levels.
8.4.2.2.2
Analysis Sets
The Per Protocol Set will be used for the primary immunogenicity analysis and a 
supporting analysis will be performed using the Evaluable Set, as noted in Section 8.3.4. 
Evaluable Set – Immunogenicity Analysis. Duplicate tables of primary and secondary 
immunogenicity analyses may also be produced based on the Evaluable population if 
there is >1% difference in the total number of subjects between the Per-Protocol 
Population and the Evaluable Population. 
8.4.2.2.3
Statistical Methods
All statistical analyses for HI titers will be performed on the logarithmically transformed 
(base 10) values. Individual HI titers below the detection limit (<10) will be set to half of 
that limit (5).
Co-primary immunogenicity endpoints of GMT and SCR for each virus strain contained 
in the vaccine will be assessed for subjects ≥ 65 years overall. For A/H1N1 and A/H3N2 
strains the two aTIV groups will be pooled. 
Primary analysis will be performed for subjects ≥ 65 years for the Per-Protocol Set. The 
difference in SCRs will be presented with exact 95% (CIs). Each of the four strains will
be analyzed separately.
For immunogenicity data, it may be reasonable to consider missing immunogenicity
values as missing completely at random (MCAR), i.e. not informative. Therefore, the 
immunogenicity analysis will comprise a complete case analysis only, without 
introducing any bias. Imputation methods will not be used.
To determine the GMT ratio (adjusted analysis) a general linear model (GLM) will be 
fitted on log transformed (base ten) post-vaccination HI titer as the outcome variable and 
terms for covariates: vaccine treatment, pre-vaccination HI titer, age stratum, gender, 
vaccination history, age-by-vaccine interaction and study site. Potential covariate 
interaction effects will also be examined in the fit of the GLM. From the model, an 
adjusted difference in least square means (on the log scale) will be produced with 95% 
confidence limits. The estimated difference and the confidence limits will be back 
transformed to obtain an adjusted GMT ratio with 95% confidence limits. Each of the 
four strains will be analyzed separately. The adjusted GMT ratio will be the result for 
which the non-inferiority assessment of the HI GMT co-primary endpoint will be based 
on. 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 82 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
The statistical models might be reduced in case they fail to converge. Further details will
be provided in the Statistical Analysis Plan.
The complete set of covariates that may be used in the model to calculate the adjusted 
GMT ratio will include treatment group (3 treatments), age sub-group (3 categories, (≥65-
74, ≥75-84, and ≥85years), sex (male or female), influenza vaccination received prior 
year (Y or N), prevaccination mean GMT titer (value) and investigator site (site 
identifier)
The GLM specification is: Adjusted Analysis GMT Model: Log-transformed Post-
vaccination HI Titer = Vaccine + Age Strata + Gender + Vaccination History [y/n] + Log-
transformed Prevaccination HI Titer + Site + Age Strata*Vaccine.
For any strain, the interaction term Age Strata*Vaccine will be removed from the fit of 
the model if it is assessed to be not significant.
The measure of the unadjusted GMT ratio based on post-vaccination GMTs only will also 
be presented.
In line with the FDA Guidance on seasonal inactivated influenza vaccines (Guidance for 
Industry Clinical Data Needed to Support Licensure of Seasonal Inactivated Influenza 
Vaccines 2007).  aQIV will be considered to be noninferior to aTIV if, for each of the 
four strains, the following statistical criteria are met: 

The upper bound of the two-sided 95% Confidence Interval (CI) for the ratio of 
the GMTs does not exceed 1.5. The GMT ratio will be calculated by GMTaTIV/
GMTaQIV

The upper bound of the two-sided 95% CI for the difference between the SCRs 
does not exceed 10%. The difference in SCR will be calculated by πaTIV – πaQIV
To achieve the CBER criteria: 

The lower bound of the two-sided 95% confidence interval for the percentage of 
subjects achieving seroconversion for HI antibody should meet or exceed 30%

The lower bound of the two-sided 95% confidence interval for the percentage of 
subjects achieving an HI antibody titer ≥ 40 should meet or exceed 60%
Binary data (ie, percentages of subjects with seroconversion and with titer ≥ 1:40) will be 
summarized for each group using unadjusted estimates and will be reported together with 
two-sided exact 95% CIs. No multiplicity adjustment to the CI levels will be 
implemented.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 83 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Handling of missing values for Immunogenicity Data:
For immunogenicity data, it may be reasonable to consider missing immunogenicity
values as missing completely at random (MCAR), ie, not informative. Therefore, the key
secondary analysis will comprise a complete case analysis only, without introducing any
bias. Imputation methods will not be used. Further details of the statistical methods will 
be provided in the SAP.
8.4.3
Analysis of Secondary Objective(s)
8.4.3.1
Analysis of Secondary Safety Objective(s)
Not applicable.
8.4.3.2
Analysis of Secondary Efficacy Objective(s)
Not applicable.
8.4.3.3
Analysis of Secondary Immunogenicity Objective(s)
Characterization of immunogenicity of aQIV, aTIV-1 and aTIV-2:
The measures of immunogenicity of aQIV, aTIV-1 and aTIV-2 will be assessed in terms 
of HI antibodies. Serum HI antibody titers against the 4 influenza vaccine strains will be 
used to calculate: 

GMT: Geometric mean of HI titers on Day 1 and Day 22

GMR: The geometric mean of the fold increase of post- vaccination HI titer over 
the pre-vaccination HI titer (Day 22/Day 1)

The percentage of subjects with a titer ≥ 1:40 at Day 1 and Day 22

SCR: the percentage of subjects with either a prevaccination HI titer < 1:10 and a 
postvaccination HI titer ≥ 1:40 or a prevaccination titer ≥ 1:10 and a ≥ 4-fold 
increase in postvaccination titer on Day 22
Superiority of immunologic response for aQIV vs aTIV:
Superiority of aQIV over aTIV-1 and aTIV-2 for antibody response to the alternate B 
strain will be assessed using the GMT ratio (GMTaTIV/GMTaQIV) and difference in SCR 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 84 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
(SCRaTIV – SCRaQIV) at Day 22. Point estimates and 95% confidence limits will be 
obtained as described for the primary endpoint. Superiority will be declared if the upper 
limit of the two-sided 95% CI for the difference in SCRaTIV – SCRaQIV) is < 0 and the 
upper limit of the two-sided 95% CI for the GMT ratio (GMTaTIV/GMTaQIV) is < 1 for 
both B strains.
8.4.3.3.1
Statistical Hypotheses
No statistical testing will be performed for the first secondary immunogenicity
objectives.
Superiority of B-strain response (geometric mean titers and proportions of subjects with 
seroconversion):
For superiority of aQIV B strain response, the hypotheses are that immunologically aQIV 
is superior compared to aTIV-1 and aTIV-2 for the B strain that is not included in each 
TIV vaccine separately. In mathematical form, these are:
H0k
(GMT): GMTrk ≥1  vs H1k
(GMT) GMTrk <1  for k=1,2
and
H0k
(SCR): Dk ≥0  vs H1k
(SCR) Dk <0  for k=1,2
where GMTrk is the ratio of geometric mean titer GMTaTIV-k/GMTaQIV of mismatched B 
strain for k=1, 2, and Dk is the differences πaTIV-k –π\aQIV of mismatched B strain Day 22 
SCR differences for k=1,2.
8.4.3.3.2
Analysis Sets
The secondary objective superiority testing will be performed using the Per Protocol Set 
(PPS).
8.4.3.3.3
Statistical Methods
All statistical analyses for HI titers will be performed on the logarithmically transformed 
(base 10) values. Individual HI titers below detection limit (<10) will be set to half of that 
limit (5).
Unadjusted for GMTs, GMRs and pertaining two-sided 95% CIs will be calculated 
assuming log-normal distribution of the titers and will be completed by providing 
minimum, maximum and median titers for each vaccine group. 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 85 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Binary data (ie, percentages of subjects with seroconversion and with titer ≥ 1:40) will be 
summarized for each group using crude estimates and will be reported together with 2-
sided exact 95% CIs. No multiplicity adjustment to the CI levels will be implemented. 
For immunogenicity data, it may be reasonable to consider missing immunogenicity 
values as missing completely at random (MCAR), ie, not informative. Therefore, the key 
secondary analysis will comprise a complete case analysis only, without introducing any 
bias. Imputation methods will not be used.
Further details of the statistical methods will be provided in the SAP.
8.4.4 Secondary Safety Objective
8.4.4.1
Analysis of Extent of Exposure
The number and percentage of subjects actually receiving the vaccination will be 
summarized by vaccine group.
8.4.4.2
Analysis of Solicited Local, Systemic and Other Adverse Events
Solicited local AEs include: injection site erythema, induration, ecchymosis and pain.
Solicited systemic AEs include: loss of appetite, nausea, fatigue, generalized myalgia,
generalized arthralgia, headache, chills, vomiting, diarrhea.
All solicited adverse events will be summarized according to defined severity grading 
scales.
Frequencies and percentages of subjects experiencing each adverse event will be 
presented for each symptom severity. Summary tables showing the occurrence of any 
local or systemic adverse event overall and at each time point will also be presented.
Postvaccination solicited adverse events reported from Day 1 to Day 7 will be 
summarized for the intervals Day 1-3, Day 4-7, Day 1-7 by maximal severity and by 
vaccine group, excluding the 30-minute measurement, which will be summarized 
separately. Injection-site erythema, ecchymosis and induration will be summarized 
according to categories based on linear measurements. Please refer to the SAP for 
definitions of categories. 
Injection site pain and systemic adverse events (except fever) occurring up to 7 days after 
each vaccination will be summarized according to “mild”, “moderate” or “severe” 
categories. For the definition of severity grades please refer to Section 7.1.1, Solicited 
Adverse Events of the protocol.
Each solicited local and systemic adverse event will also be further summarized as “none” 
versus “any”. “Any” will include measurements with a diameter of at least 1 mm.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 86 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Implausible measurements (for further definition see SAP) will be left out of the analysis.
Use of antipyretics and analgesics will be summarized by frequency and percentage of 
subjects reporting use. Summaries by type of use (prophylactic versus treatment) and by 
vaccine group will be provided. The influence of antipyretics and analgesics use on the 
occurrence of specific adverse events (e.g., fever, pain) may be assessed.
Body temperature will be summarized by 0.5 °C and 1.0 °C increments from 36.0 °C up 
to ≥40 °C and will be broken down according by route of measurement. In addition, fever 
will be summarized according to “mild”, “moderate” or “severe” categorization. For the 
definition of severity grades please refer to the SAP.
8.4.4.3
Analysis of Unsolicited Adverse Events
This analysis applies to all adverse events occurring during the study, judged either as 
probably related, possibly related, or not related to vaccination by the Investigator, 
recorded in AE CRF, with a start date on or after the date of first vaccination. AE starting 
prior to the first vaccination will only be listed. The original verbatim terms used by 
investigators to identify adverse events in the CRFs will be mapped to preferred terms 
using the MedDRA dictionary. The adverse events will then be grouped by MedDRA 
preferred terms into frequency tables according to system organ class.
All reported adverse events, as well as adverse events judged by the investigator as at 
least possibly related to study vaccine, will be summarized according to system organ 
class and preferred term within system organ class (SOC). These summaries will be 
presented by vaccination group and by interval of study observation. When an adverse 
event occurs more than once for a subject, the maximal severity and strongest relationship 
to the vaccine group will be counted.
Separate summaries will be produced for the following categories:

Serious adverse events

Adverse events that are possibly or probably related to vaccine

Adverse events of special interest

New onset of chronic disease

Adverse events leading to withdrawal

Adverse events resulting in death
Data listings of all adverse events will be provided by subject. In addition, adverse events 
in the categories above will be provided as listed data.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 87 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
For handling of missing data, the entire study period will be divided into disjoint intervals 
based upon the time and event schedule in the protocol:
Solicited AEs: 30 min, 6h-Day 3, Day 4-Day 7, and one overall interval: 6h-Day 7.
Unsolicited AEs: [Day 1-22], [Day 23-181], and [Day 1-181].
No imputation of missing solicited or unsolicited AEs will be used. The percentage of 
subjects with missing solicited AE assessments (eg, missing Diary Card) and missing 
Safety Phone Call or safety assessment will be reported for each time period.
8.4.4.4
Analysis of Safety Laboratory Values
Not applicable.
8.4.5 Analysis of Exploratory Objectives
The exploratory objectives are:
1. Additional optional objectives include characterization of the immunogenicity of 
aQIV using other immunological assays (e.g., virus neutralization [MN] or anti-
neuraminidase antibody assays may be performed)
2. To explore the association between immune response after administration of aQIV 
or the aTIV-1, containing the same virus strains as the US-licensed adjuvanted 
trivalent influenza vaccine, or the aTIV-2 containing the alternate B strain by 
baseline characteristics.
Exploratory immunogenicity objective 1
Exploratory objectives related to the MN-assay, immune response to heterologous 
influenza strains, or different antigens will be evaluated using similar methods for log
normal. binomial data, and GMT and SCR as described in the statistical method for 
primary and secondary immunogenicity analysis.
Exploratory immunogenicity objective 2

GMTs: Geometric mean of HI titers prevaccination (Day 1) and at Study Exit 
Visit

Percentage of subjects with four-fold rise
Analyses of the exploratory immunogenicity endpoints will be performed with adjustment 
for covariates including prevaccination titer, vaccination history, age and gender to 
evaluate the contribution of these factors to variations in the immune response. The 
covariate adjustment will be performed with all of the specified covariates in the general 
linear model.
The full model specification for the GMT titers will be:
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 88 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Log-transformed Post-Vaccination HI Titer = Vaccine + Age Strata + Gender+ 
Vaccination History + Log-transformed Prevaccination HI Titer. 
The full model specification for the SCR rates will be:
SCR = Vaccine + Age Strata + Gender + Vaccination History + Log-transformed Pre-
vaccination HI titer 
Seroconversion rates will be analyzed using a logistic regression model, and GMT titers 
will be log transformed (base 10) and analyzed with a general linear model. Pre-
vaccination titers will be log transformed and entered as a continuous covariate. 
Vaccination history will be a categorical variable indicating whether or not an individual 
received an influenza vaccination in the previous year. If the proportion vaccinated in the 
previous year is close to 100% then this covariate may be omitted to avoid creating an 
unstable model. Age will be entered according to the predefined strata (≥65-74, ≥75-84, 
and ≥85years). For the logistic regressions, the odds ratios will be presented with 95% 
CIs for each effect in the model. For the GLM least square mean estimates for the GMT 
ratio will be presented with 95% confidence limits for each effect in the model. 
Further details of the analysis of exploratory be provided in the SAP.
8.5
Sample Size and Power Considerations
aQIV will be tested against aTIV comparators. The treatment randomization ratio is 2:1:1 
(aQIV: aTIV-1: aTIV-2). This study is powered to achieve 80% power to demonstrate 
noninferiority over 8 co-primary endpoints, seroconversion rates for 4 strains, GMT for 4 
strains using a one-sided alpha of 0.025 for each comparison. No adjustment for multiple 
endpoints will be made.
For comparisons of SCR a noninferiority margin of 10% (aTIV – aQIV) will be 
employed. It is assumed that the SCRs for A/ H1N1, A/ H3N2 and B strains for TIV are 
73%, 73% and 40% respectively. These estimates are based on the estimated SCR rates of 
historical data, namely study protocol V70_27. It has been assumed that there is no 
difference in terms of SCR between aQIV and aTIV for all strains. For comparison of the 
GMT ratio, a noninferiority of 1.5 (aTIV/aQIV) will be employed. It is assumed that there 
is no difference between aQIV and aTIV (i.e., a ratio of 1) and that the standard deviation 
of log (titer) is 1.2.
Under these assumptions, N evaluable = 800 in the aQIV group and 400 in each aTIV 
group providing 800 and 800 subjects receiving aQIV and aTIV respectively for 
comparisons of A strains, and 800 and 400 subjects receiving aQIV and aTIV 
respectively for comparisons of B strains. This provides a total N evaluable = 1600. These 
numbers provide 99.45% power to detect differences in SCR for each A strain and 91.29 
% power for each B strain, providing overall 82.42% power for the 4 SCR tests.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 89 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
For GMT ratio tests each A strain test will have 100% power and each B strain test will 
have 99.98% power, providing 99.96% power for the 4 GMT ratio tests and consequently 
82.39% power for the 8 co-primary endpoints.  Overall 1600 evaluable subjects will be 
required. Allowing for a 10% drop-out N=1778 subjects will be recruited (Sample size 
calculations were performed using PASS v12).
The immunogenicity was powered to meet the criteria prespecified in the CBER guidance 
for acceptable immunogenicity: namely, 

the lower bound of the two-sided 95% confidence interval for the percent of 
subjects achieving seroconversion should exceed 30%, and 

the lower bound of the two-sided 95% confidence interval for the percent of 
subject achieving HI antibody titer ≥ 40 should exceed 60%
With a sample size of N=800 (evaluable) subjects for the aQIV group if the population 
SCR for A/ H1N1, A/ H3N2 and B strains for TIV is 73%, 73% and 40% respectively 
then the probability of observing a seroconversion rate that is significantly greater than 
30% is approximately 100% (for the A/H1N1), 100%for A/H3N2 and 100% (for the B-
strains).
With a sample size of N=800 (evaluable) subjects for the aQIV group if the population SP 
rates for A/ H1N1, A/ H3N2 and B strains for TIV is 91%, 99% and 64.6% respectively 
(as observed in V70_27) then the probability of observing a SP rate that is significantly 
greater than 60% is approximately 100% (for the A/H1N1), 100% for A/H3N2 and 
76.47% (for the B-strains).
Table 8.5-1 summarizes the list of all co-primary endpoints with strains, the planned
noninferiority margin and underlying assumptions used for the sample size computations.
Table 8.5-1: Summary of Assumptions Used for Sample Size Calculations
NI comparison
H1N1
H3N2
B strains
Test significance level, alpha (1-sided)
2.50%
2.50%
2.50%
Noninferiority Margin for the SCR 
comparison (%)
10
10
10
Assumed true SCR
73%
73%
40%
Power for SCR comparison tests for 
99.45%
99.45%
91.29%
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 90 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
each strain (%)
Global Power for 4 SCR Endpoints
82.42%
Noninferiority Margin for the GMT 
ratio
1.5
1.5
1.5
Common Standard Deviation of 
loge(titer) 
1.2
1.2
1.2
Power for GMT ratio tests for each 
strain (%)
99.99%
99.99%
99.98%
Global Power for 4 GMT ratio 
Endpoints
99.96%
Global Power for 8 Co-primary 
Endpoints
82.39%
CBER Criteria
H1N1
H3N2
B strains
Test significance level, alpha (1-sided)
2.50%
2.50%
2.50%
Seroconversion Threshold
30%
30%
30%
Assumed true SCR
73%
73%
40%
Power for SCR 
100%
100%
100%
Global Power for 4 SCR Endpoints
100%
Threshold for Rate > 1:40
60%
60%
60%
Assumed True Rate > 1:40
91%
99%
64.6%
Power for Rate > 1:40
100%
100%
76.47%
Global Power for 4 > 1:40 Endpoints
76.47%
Global Power for the Second 8 Co-
76.47%
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 91 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
primary Endpoints (CBER Criteria)
A safety database of N = 800 has a 95% chance of detecting AEs that occur at a rate of 1 
in 267. With a single stratum of 800 participants, the probability of observing at least one 
event for events with population rates of 1 in 300, 1 in 200, and 1 in 100 are 93.1%, 
98.2% and 100%, respectively. 
8.6
Interim Analysis
No interim analysis is planned for this study.
.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 92 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
9.
SOURCE DOCUMENTATION, STUDY MONITORING AND AUDITING
In order to ensure consistency across sites, study monitoring and auditing will be 
standardized and performed in accordance with the Sponsor’s or delegated contract 
research organization’s (CRO) standard operating procedures and applicable regulatory 
requirements (eg, FDA, EMA, and ICH guidelines).
Prior to enrollment of the first study subject, Seqirus or delegate will train investigators 
and/or their study staff on the study protocol, all applicable study procedures, 
documentation practices and all electronic systems. CRFs supplied by the Sponsor must 
be completed for each enrolled subject (see Section 8.3.1, All Enrolled Set for definition 
of enrolled subject). Documentation of screened but not enrolled subjects must be 
maintained at the site and made available for review by the site monitor. Data and 
documents will be checked by the Sponsor and/or monitor.
9.1
Source Documentation
Prior to the start of the study, the site staff participating in the study conduct will be 
instructed on what documents will be required for review as source documents. The kinds 
of documents that will serve as source documents will be agreed between Sponsor or 
delegate and Investigator and designees and specified in the SDA prior to subject 
enrollment.
In addition, source documentation must include all of the following: subject identification 
(on each page), eligibility and participation, proper informed consent procedures, dates of 
visits, adherence to protocol procedures, adequate reporting and follow-up of adverse 
events, documentation of prior/concomitant medication/vaccines, study vaccine 
receipt/dispensing/return records, study vaccine administration information, any data 
collected by a telephone conversation with the subject and date of completion and reason.
The subject must also allow access to the subject’s medical records. Each subject must be 
informed of this prior to the start of the study and consent for access to medical records 
that may be required in accordance with local regulations.
All safety data reported by subjects must be written down in source documents prior to 
entry of the data into CRFs. If there are multiple sources of information (e.g., Diary Card, 
verbal report of the subject, telephone contact details, medical chart) supporting the 
diagnosis of an adverse event, these sources must be identified in the source documents, 
discrepancies between sources clarified, the ultimate diagnosis must be justified and 
written in the source documents, and this diagnosis must be captured in the Adverse 
Event CRF (AE CRF). The AE CRF must also capture which source(s) of information 
were used to determine the adverse event (e.g. subject recall, medical chart, Diary Card).
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 93 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
9.2
Study Monitoring, Auditing and Source Data Verification
Prior to enrollment of the first study subject, Seqirus or its designee (eg, a CRO) will 
develop a Clinical Monitoring Plan to specify how centralized and/or on-site monitoring, 
including clinical specimens reconciliation, will be performed for the study. Study 
progress will be monitored by Seqirus or its designee as frequently as necessary to ensure:

that the rights and well-being of human subjects are protected

the reported study data are accurate, complete, and verifiable from the source 
documents and

the conduct of the study is in compliance with the current approved 
protocol/amendment(s), GCP and applicable regulatory requirements
Contact details for the Seqirus team or its designee involved in study monitoring will be 
provided to the Investigator. Study data recorded on CRFs will be verified by checking 
the CRF entries against source documents in order to ensure data completeness and 
accuracy as required by the study protocol. 
Data verification may also be performed through a centralized review of data (eg, 
checking for outliers or other anomalies). Additional documents such as the Investigator 
Site File, pharmacy records, and informed consent documentation must also be available 
for review if requested. Arrangements for monitoring visits will be made in advance in 
accordance with the monitoring plan, except in case of emergency.
The Investigator and/or site staff must make source documents of subjects enrolled in this 
study available for inspection by Seqirus or its representative at the time of each 
monitoring visit and Sponsor audits, when applicable. These documents must also be 
available for inspection, verification and copying, as required by regulations, by officials 
of the regulatory health authorities (e.g. FDA, EMA and others) and/or ECs/IRBs. The 
Investigator and study site staff must comply with applicable privacy, data protection and 
medical confidentiality laws for use and disclosure of information related to the study and 
enrolled subjects.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 94 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
10.
DATA MANAGEMENT
10.1
Data Entry and Management
In this study, all clinical data (including, but not limited to, AE/SAEs, concomitant 
medications, medical history, and physical assessments), safety data, and immunogenicity 
data will be entered onto case report forms (CRFs) in a timely fashion by the Investigator 
and/or the Investigator’s dedicated site staff. Data entered onto CRFs are stored on a 
secure website. The data collected on this secure website are assimilated into an 
electronic data capture (EDC) system, which is compliant with Title 21 Part 11 policies of 
the Code of Federal Regulations (FDA, 1997). The data system includes password 
protection and internal quality checks. The EDC system will be designed and validated by 
the Sponsor prior to activation for data entry by sites. The Investigator or designated 
delegate must review data entered and electronically sign the CRFs to verify their 
accuracy.
Access to the EDC system for data entry or review will require training and distinct 
individual access code assignments to those site staff members who will be entering study 
data and those involved in study oversight who may review study data. Data are collected 
within the EDC system, to which the Sponsor and site monitors have exclusively “read 
only” access.
10.2
Data Clarification
As part of the conduct of the trial, the Sponsor may have questions about the data entered 
by the site, referred to as queries. The monitors and the Sponsor are the only parties that 
can generate a query. All corrections and clarifications will be entered into the EDC 
system and will be identified by the person entering the information, the reason for the 
change, as well as the time of the changes made. If changes are made to a previously and 
electronically signed CRF, the investigator must confirm and endorse the changes.
10.3
Data Protection
Seqirus respects the subjects’ rights to privacy and will ensure the confidentiality of their 
medical information in accordance with all applicable laws and regulations.
The Sponsor as Data Controller according to the European Directive on the protection of 
individuals with regard to the processing of personal data and on the free movement of 
such data (European Parliament, 1995) confirms herewith compliance to Directive 
95/46/EC in all stages of Data Management.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 95 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
11.
RECORD RETENTION
Investigators must retain all study records required by Seqirus and by the applicable 
regulations in a secure and safe facility. The Investigator must consult a Seqirus
representative before disposal of any study records, and must notify the Sponsor of any 
change in the location, disposition, or custody of the study files. Essential documents 
must be retained for 15 years. “Essential documents” are defined as documents that 
individually and collectively permit evaluation of the conduct of a study and the quality 
of the data produced. These documents should be retained for a longer period, however, if 
required by the applicable national regulatory or institutional requirements. 
Laboratory samples will be retained for a period of up to 15 years.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 96 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
12.
USE OF INFORMATION AND PUBLICATION
Seqirus assures that the key design elements of this protocol will be posted in a publicly 
accessible database such as clinicaltrials.gov, and in compliance with current regulations.
Seqirus also assures that key results of this clinical study will be posted in a publicly 
accessible database within the required time-frame from the end of study as defined in 
Section 3.9, End of Study.
In accordance with standard editorial, ethical practices and current guidelines of Good 
Publication Practice (Graf, 2009), Seqirus will generally support publication of 
multicenter studies only in their entirety and not as individual center data. In this case, a
Coordinating Investigator will be designated by mutual agreement prior to the start of the 
study. The Coordinating Investigator will also sign the clinical study report on behalf of 
the Principal Investigators (CPMP, 2001). Authorship will be determined by mutual 
agreement and in line with International Committee of Medical Journal Editors authorship 
requirements. Any formal publication of the study in which contribution of Seqirus
personnel exceeded that of conventional monitoring will be considered as a joint 
publication by the investigator and the appropriate Seqirus personnel.
Seqirus must be notified of any intent to publish data collected from the study and prior 
approval from Seqirus must be obtained prior to submission for publication.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 97 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
13.
ETHICAL CONSIDERATIONS
13.1
Regulatory and Ethical Compliance
The study will be conducted in compliance with the protocol, GCP and applicable 
regulatory requirement(s).
This clinical study was designed and shall be implemented and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with 
applicable local regulations: including European Directive 2001/20/EC, US Code of 
Federal Regulations Title 21, and Japanese Ministry of Health, Labor, and Welfare. 
Seqirus codes on protection of human rights, and with the ethical principles laid down in 
the Declaration of Helsinki (European Council 2001, US Code of Federal Regulations, 
ICH, 1997).
13.2
Informed Consent Procedures
Eligible subjects may only be included in the study after providing written informed 
consent, as described in Section 5.1.1, Informed Consent. Before the start of the study, the 
Investigator will have the informed consent and any other materials that will be provided 
to the subjects reviewed and approved by the IRB/EC. This review and approval will be 
documented and stored with other study documents. The Investigator or designee must 
fully inform the subject or legal representative of all pertinent aspects of the study. A 
copy of the written informed consent will be given to the subject or the designee. The 
subject/designee must be allowed ample time to ask about the details of the study and to 
make a decision as to whether or not to participate in the study. The subject (and/or legal 
representative(s) must sign the consent form indicating their agreement to participate in 
the study before any study-related procedures are conducted. The informed consent 
process may be conducted up to 10 days prior to vaccination on Day 1. If the subject 
and/or legal representative(s) is unable to read and write, a witness must be present during 
the informed consent discussion and at the time of informed consent signature.
Prior to the start of the study, Seqirus will provide to investigators a proposed informed 
consent form that complies with the ICH GCP guideline and regulatory requirements and 
is considered appropriate for this study. Any changes to the proposed consent form 
suggested by the investigator must be agreed to by Seqirus before submission to the 
IRB/EC and a copy of the approved version must be provided to the Seqirus monitor after 
IRB/EC approval.
13.3
Responsibilities of the Investigator and IRB/EC
The protocol and the proposed informed consent form must be reviewed and approved by 
a properly constituted IRB/EC before study start. Properly constituted IRB/EC is defined 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 98 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
in ICH Guideline for Good Clinical Practice E6 (R1), Section 3 (ICH, 1997), and 
Integrated Addendum to ICH E6(R2): Guideline for Good Clinical Practice (ICH, 2016). 
A signed and dated statement that the protocol and informed consent have been approved 
by the IRB/EC must be given to Seqirus before study initiation. Prior to study start and at 
any time the protocol is amended during study conduct, the Investigator is required to 
sign a protocol signature page confirming his/her agreement to conduct the study in 
accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to Seqirus monitors, auditors, 
Seqirus Clinical Quality Assurance representatives, designated agents of Seqirus, 
IRBs/ECs, and regulatory authorities as required. If an inspection of the clinical site is 
requested by a regulatory authority, the investigator must inform Seqirus immediately that 
this request has been made.
The Investigator also responsible for the following:

Maintaining a list of appropriately qualified persons to whom the Investigator has 
delegated significant study-related duties

Demonstrating the capability of recruiting the required number of suitable subjects 
within the recruitment period.

Demonstrating sufficient time and staffing to properly conduct and complete the study 
within the agreed study period.

Ensuring that all persons assisting with the study are adequately informed about the 
protocol, the investigational product(s), and their study-related duties and functions

Ensuring that appropriately trained health care professionals are responsible for all 
study-related medical decisions and for ensuring appropriate medical care of subjects 
experiencing any adverse event related to the study

If permission to do so is given by the subject (or legal representative), ensuring that 
the subject’s primary healthcare provider is informed of the subject’s participation in 
the study
The Investigator should not implement any deviation from, or changes of the protocol 
without agreement by the Sponsor and prior review and documented approval/favorable
opinion from the IRB/IEC of an amendment, except where necessary to eliminate an 
immediate hazard(s) to study subjects, or when the change(s) involves only logistical or 
administrative aspects of the study (e.g. change in monitor(s), change of telephone 
number(s)). In addition, the Investigator, or person designated by the Investigator, should 
document and explain any deviation from the approved protocol.
The Investigator may implement a deviation from, or a change of, the protocol to 
eliminate an immediate hazard(s) to study subjects without prior IRB/IEC 
approval/favorable opinion. As soon as possible, the implemented deviation or change, 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 99 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
the reasons for it, and, if appropriate, the proposed protocol amendment(s) should be 
submitted:
(a) to the IRB/IEC for review and approval/favorable opinion
(b) to the Sponsor for agreement and, if required
(c) to the regulatory authority(ies)
13.4
Protocol Amendments
An amendment is a written description of change(s) to or formal clarification of a study 
protocol which may impact on the conduct of the clinical study, potential benefit of the 
clinical study, or may affect subject safety, including changes of study objectives, study 
design, subject population, sample sizes, study procedures, or significant administrative 
aspects. An administrative change of a study protocol is a minor correction or 
clarification that has no significant impact on the way the clinical study is to be conducted 
and no effect on subject safety (e.g. change of telephone number(s), logistical changes). 
Protocol amendments must be approved by Seqirus, health authorities where required, 
and the IRB/EC. In cases when the amendment is required in order to protect the subject 
safety, the amendment can be implemented prior to IRB/EC approval. Notwithstanding, 
the need for formal approval of a protocol amendment, the Investigator is expected to take 
any immediate action required for the safety of any subject included in this study, even if 
this action represents a deviation from the protocol. In such cases, Seqirus should be 
notified of this action, the IRB/EC at the study site, and, if required by local regulations, 
the relevant health authority) should be informed within 10 working days.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 100 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
14.
REFERENCE LIST
Hak EF. Development and validation of a clinical prediction rule for hospitalization due 
to pneumonia or influenza or death during influenza epidemics among community-
dwelling elderly persons. J Infect Dis 2004;189(3):450-458.
Food & Drug Administration (FDA). Guidance for Industry: Clinical Data Needed to 
Support the Licensure of Seasonal Inactivated Influenza Vaccines. U S Food and Drug 
Administration Home Page, Center for Biologics Evaluation and Research, May 2007.
Temte JL, Prunuske JP. Seasonal influenza in primary care settings: review for primary 
care physicians. WMJ 2010 Aug;109(4):193-200.
Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med 
2008 Apr;121(4):258-64.
Fiore AE, Shay DK, Broder K et al. Prevention and control of seasonal influenza with 
vaccines: recommendations of the Advisory Committee on Immunization Practices 
(ACIP), 2009. MMWR Recomm Rep 2009 Jul 31;58(RR-8):1-52.
Monto AS. Epidemiology of influenza. Vaccine 2008 Sep 12; 26 Suppl 4:D45-8.
Osterholm, MT, Kelley NS et al. Efficacy and effectiveness of influenza vaccines: a 
systematic review and meta-analysis. Lancet Infect Dis 2012;12(1): 36-44.
Beyer WE, McElhaney J, et al. Cochrane re-arranged: support for policies to vaccinate 
elderly people against influenza. Vaccine 2013;31(50): 6030-6033.
Goodwin K, Viboud C et al. Antibody response to influenza vaccination in the elderly: a 
quantitative review. Vaccine 2006;24(8):1159-1169.
Sasaki S, Sullivan M, et. al. Limited efficacy of inactivated influenza vaccine in elderly 
individual is associated with decreased production of vaccine-specific antibodies. J Clin 
Invest 2011;121(8): 3109-3119.
Frey SE et al. Comparison of the safety and immunogenicity of anMF59-adjuvanted with 
a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 2014;32:5027-
5034.
Rota PA, Wallis TR, Harmon MW et al. Cocirculation of two distinct evolutionary 
lineages of influenza type B virus since 1983. Virology 1990;175(1):59-68.
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 101 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin 
Immunother 2012; 8(1):81-8.
Lo YC, Chuang JH et al. Surveillance and vaccine effectiveness of an influenza epidemic 
predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 
2011-12 season. PLoS One 2013;8(3): e58222.
Belshe, RB.  The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 
28 Suppl 4: D45-53.
World Health Organization (WHO); Recommended composition of influenza virus 
vaccines for use in the 2017-2018 northern hemisphere influenza season. Accessed 11 
May 2017 at: 
http://www.who.int/influenza/vaccines/virus/recommendations/2017_18_north/en/
Centers for Disease Control and Prevention (CDC) (2014). Antigenic Characterization. 
Accessed 16 May 2017 at: www.cdc.gov/flu/professionals/laboratory/antigenic.htm 
Code of Federal Regulations (1997): Food and Drug Administration, U.S. Department of 
Health and Human Services: Title 21, Part 11: Electronic Records Electronic Signatures. 
Federal Register 62: 13464
European Parliament (1995): Directive 95/46/EC of the European Parliament and of the 
Council of 4 April 2001. Official Journal of the European Communities. L 281/31-39
Graf C, Battisti WP, Bridges D. Good publication practice for communicating company 
sponsored medical research: the GPP2 guidelines. BMJ 2009;339: b4330
Committee for Proprietary Medicinal Products (CPMP) (2001): Note for Guidance on 
Coordinating Investigator Signature of Clinical Study Reports. The European Agency for 
the Evaluation of Medicinal Products.
European Parliament (2001): Directive 2001/20/EC of the European Parliament and of 
the Council of 4 April 2001. Official Journal of the European Communities. L 121/34-44
ICH (1997) ICH Harmonised Tripartite ICH Guideline for Good Clinical Practices E6 
(R1). Federal Register, 62 (90): 25691-25709
ICH (2016) ICH Harmonised Guideline Integrated Addendum to ICH E6(R1): Guideline 
for Good Clinical Practice E6(R2). Accessed 12 May 2017 at: 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6
_R2__Step_4.pdf
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 102 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
ICH (1998) ICH Harmonised Tripartite ICH Guideline for Statistical Principles for 
Clinical Trials E9. Federal Register, 63 (179): 49583
U.S. Department of Health and Human Services, Food and Drug Administration, CBER 
(2009): Guidance for Industry Patient-Reported Outcome Measures: Use in Medical 
Product Development to Support Labeling Claims
59th World Medical Association General Assembly (October 2008) Declaration of 
Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Seoul, 
Korea
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 103 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
APPENDIX 1: EXAMPLES OF PRE-EXISTING MEDICAL CONDITIONS FOR 
CALCULATION OF RISK SCORE
1. 
Pulmonary Disease
a. Asthma
b. Chronic bronchitis
c. Chronic obstructive lung disease or emphysema
d. Pneumoconioses
e. Pulmonary fibrosis
f. Pulmonary tuberculosis and diseases due to other mycobacteria
g. Sarcoidosis
2. 
Heart Disease
h. Coronary artery disease
i. Valvular heart disease
j. Congenital heart disease
k. Hypertensive heart disease
l. Ischemic heart disease
m. Diseases of pulmonary circulation
n. Myocarditis
o. Arrhythmias, including atrial fibrillation
p. Congestive heart failure
3. Renal Disease
q. Hypertensive renal disease
r. Dialysis
s. Renal transplantation
t. Nephritis, nephrotic syndrome, nephrosis
u. Chronic pyelonephritis
v. Dialysis and transplant
4. 
Dementia or stroke
w. Neurologic and neurodevelopmental conditions [including disorders of the 
brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy 
Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc.
Confidential
Protocol V118_20
18 May 17 Version 1.0
Page 104 of 104
PRO-01 TEMP 06 / Atlas No. 293620
Version No.4 / Version Date: January 29, 2015
(seizure disorders), stroke, intellectual disability (mental retardation), moderate to 
severe developmental delay, muscular dystrophy, or spinal cord injury].
x. Cerebrovascular disease
y. Dementia
z. Hereditary and degenerative diseases of CNS
5. 
Non-hematological and hematological cancer (excluding cancer of the skin 
other than melanoma)
Doc ID: 83409929, Version: 1, Approval Date: 18May17

吀栀椀猀猀椀最渀愀琀甀爀攀挀攀爀琀椀昀椀挀愀琀攀椀猀漀渀氀礀瘀愀氀椀搀眀栀攀渀愀挀挀漀洀瀀愀渀椀攀搀戀礀愀氀氀琀栀攀瀀愀最攀猀漀昀琀栀攀搀漀挀甀洀攀渀琀⸀⼀
䐀椀攀猀攀爀一愀挀栀眀攀椀猀椀猀琀渀甀爀稀甀猀愀洀洀攀渀洀椀琀愀氀氀攀渀匀攀椀琀攀渀搀攀猀䐀漀欀甀洀攀渀琀攀猀最ﰀ氀琀椀最⸀⼀
䰀愀瀀爀攀猀攀渀琀攀挀攀爀琀椀昀椀挀愀稀椀漀渀攀瘀愀氀椀搀愀猀漀氀愀洀攀渀琀攀猀攀愀挀挀漀洀瀀愀最渀愀琀愀搀愀琀甀琀琀攀氀攀瀀愀最椀渀攀搀攀氀搀漀挀甀洀攀渀琀漀挀甀椀猀椀爀椀昀攀爀椀猀挀攀
Novartis
     䐀漀挀甀洀攀渀琀䄀瀀瀀爀漀瘀愀氀䌀攀爀琀椀昀椀挀愀琀攀⼀
        䘀爀攀椀最愀戀攀渀愀挀栀眀攀椀猀䐀漀欀甀洀攀渀琀⼀
     䌀攀爀琀椀昀椀挀愀稀椀漀渀攀瀀攀爀氀’愀瀀瀀爀漀瘀愀稀椀漀渀攀搀椀甀渀搀漀挀甀洀攀渀琀漀
吀栀攀椀渀搀椀瘀椀搀甀愀氀猀氀椀猀琀攀搀栀愀瘀攀愀瀀瀀爀漀瘀攀搀琀栀椀猀搀漀挀甀洀攀渀琀昀漀爀椀洀瀀氀攀洀攀渀琀愀琀椀漀渀甀猀椀渀最愀渀攀氀攀挀琀爀漀渀椀挀猀椀最渀愀琀甀爀攀椀渀琀栀攀
䄀琀氀愀猀䔀䐀䴀匀⸀⼀䐀椀攀愀甀昀最攀昀ﰀ栀爀琀攀渀倀攀爀猀漀渀攀渀栀愀戀攀渀搀甀爀挀栀椀栀爀攀攀氀攀欀琀爀漀渀椀猀挀栀攀唀渀琀攀爀猀挀栀爀椀昀琀Ⰰ搀椀攀猀攀猀䐀漀欀甀洀攀渀琀
椀洀䄀琀氀愀猀䔀䐀䴀匀最攀渀攀栀洀椀最琀⸀⼀䰀攀瀀攀爀猀漀渀攀猀漀琀琀漀爀椀瀀漀爀琀愀琀攀栀愀渀渀漀愀瀀瀀爀漀瘀愀琀漀焀甀攀猀琀漀搀漀挀甀洀攀渀琀漀瀀攀爀
挀漀渀猀攀渀琀椀爀渀攀氀’甀琀椀氀椀稀稀漀⠀氀’愀瀀瀀爀漀瘀愀稀椀漀渀攀愀瘀瘀椀攀渀攀洀攀搀椀愀渀琀攀昀椀爀洀愀攀氀攀琀琀爀漀渀椀挀愀猀甀猀椀猀琀攀洀愀䄀琀氀愀猀䔀䐀䴀匀⤀⸀
) 
Title:  Seqirus Clinical Medical Lead 
Date: Thursday, 18 May 2017, 20:18   GMT 
Meaning: As an approver, I agree with the content and format of this document. / Als Genehmiger bin ich mit dem Inhalt und der Form
des Dokumentes einverstanden. / In qualità di Approvatore, concordo con il contenuto ed il formato di questo documento 
================================================
Doc ID: 83409929, Version: 1, Approval Date: 18May17